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a  b  s  t  r  a  c  t
Psychiatric  disorders  like  mood  disorders,  schizophrenia,  or drug  addiction  affect a sizeable  proportion  of
the human  population  and  severely  compromise  quality  of  life. Therefore,  measures  to  prevent  the  mani-
festation,  and  treatments  to  ameliorate  the symptoms,  of  these  disorders  are  in high demand.  Brain  lipids
determine  the localization  and  function  of proteins  in  the cell  membrane  of  neurons.  Lipids  may  also  act
as neurotransmitters  or other  signalling  molecules.  The  lipid composition  of  the  brain  can  be inﬂuenced
by  nutrition,  environmental  factors,  and  by  behavioural  activity.  Thus,  lipids  represent  a target  for  preven-
tive  medicine  of  psychiatric  disorders.  Here  we  review  how  brain  lipids  contribute  to  normal  behaviouratty acids
phingolipids
ndocannabinoids
epression
nxiety
and  to major  psychiatric  disorders  with  the  focus  on  phospholipids/fatty  acids,  sphingolipids,  and  endo-
cannabinoids.  Accumulating  evidence  suggests  a crucial  role for  membrane  forming  and  signalling  lipids
in the  brain  in  the  etiopathologies  of  depression,  bipolar  disorders,  schizophrenia,  and  drug  addiction.
Lipids  also represent  potential  preventive  interventions  for these  psychiatric  disorders  by either  targetedchizophrenia
ddiction
dietary  supplementation  or pharmacological  manipulation  of  lipid regulating  enzymes.
©  2016  Elsevier  Ltd. All  rights  reserved.
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. Introduction
Mental function in mammals involves the sensation and per-
eption of sensory stimuli, analysis of perceived information, and
ubjective emotional and behavioural responses to the perceived
timuli and information. It also includes how information is pro-
essed by cognitive activity, how it is stored in memory systems,
nd how it is retrieved on demand. Together, these processes deter-
ine how an organism perceives itself and how it interacts with its
nvironment and conspeciﬁcs. Deviation in one or more dimension
f mental activity from what is perceived as ‘normal’ constitutes
sychological disturbances and psychiatric disorders (Schumann
t al., 2014). The anatomical substrate of mental activity is the
rain, which operates in close interaction with all other organs of
he body (O’Mahony et al., 2015). As in peripheral organs, func-
ion of the brain depends on nutrient supply. Over time, even small
hanges in nutrition may  affect microstructure and activity of the
rain in various ways. This may  eventually affect functions as com-
lex as ‘personality’, in keeping with the proverbial consequence
f “Du bist, was Du isst” (you are what you eat; Ludwig Feuerbach).
hus, nutrition contributes not only to physical well-being, but also
ental health; whereas malnutrition, which is essentially deﬁned
y its consequences, can contribute to mental illness. In contrast,Please cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
here are certain diets that may  counteract and even reverse psychi-
tric problems induced by other factors, such as stress (Bergouignan
t al., 2009). . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . .  .  .  .  . .  .  .  .  .  . . . .  . . . . .  .  . .  .  .  .  . .  00
A major class of molecules that fundamentally determine cell
function in the brain are lipids. Lipids and/or their precursors
derived from food are taken up by the organism and used for the
maintenance of general cell function. In particular, the integrity of
cell membranes and signalling through membranes depend on lipid
homeostasis in the brain. Studies published in recent years have
provided new insights into how lipid homeostasis, most notably of
phospholipids, sphingolipids, and endocannabinoid lipids, affects
mental functions. These ﬁndings serve as the basis for a preventive
medicine approach for psychiatric disorders by which the risk for
developing psychiatric disorders may  be mitigated by interventions
that modulate lipid homeostasis in the brain. Evidence supporting
this approach is reviewed here.
2. Targeting psychiatric disorders by preventive medicine
2.1. What is preventive medicine and its application in
psychiatric disorders
A number of serious psychiatric disorders tend to emerge dur-
ing critical neurodevelopmental periods, such as adolescence, and
often lead to protracted illness phases with signiﬁcantly reduced
quality of life. Efforts aimed at the prevention of mental disordersatric disorders and preventive medicine. Neurosci. Biobehav. Rev.
include reducing incidence, prevalence, and preventing or delaying
recurrence; limiting the duration of symptoms; and decreasing the
impact of illness in the affected person, their families and society
(Mrazek and Haggerty, 1994). Prevention is important when aim-
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ng to successfully reduce the prevalence of a disease (Barrera et al.,
007; Munoz et al., 2010).
.2. Major brain lipids and how to manipulate them
Findings from animal experiments demonstrate that brain lipids
an be manipulated via multiple paths and mechanisms, but does
his also apply to the human brain, and if so, how can the brain lipids
re examined in humans? A proxy is the estimation of the effects of
utritional manipulations on brain lipids via neurological, psychi-
tric, or ophthalmological read-outs (Uauy et al., 2001). In humans,
ostmortem examination allows the direct analysis of lipids and
heir associated enzymes in the brain (O’Brien and Sampson, 1965;
pence et al., 1979; Söderberg et al., 1990; Svennerholm et al.,
994). Individual lipids can be quantiﬁed to a limited extent with
n vivo magnet resonance (MR) spectroscopy (Kwee and Nakada,
988; Pettegrew et al., 1991; Manganas et al., 2007). In fact, a
arker for neural progenitor cells of the hippocampus, which is
ost likely composed of a mixture of saturated and unsaturated
atty acids, has been described using in vivo MR  spectroscopy. This
arker is detected in high abundance in the hippocampus and in
he cortex and decreases with increasing age (Manganas et al.,
007). Analysis of brain lipids and associated enzymes in cere-
rospinal ﬂuid (CSF) can also be used as an indirect assessment of
rain lipid status (Mulder et al., 1998; Fonteh et al., 2006; Kosicek
t al., 2012; Mühle et al., 2013).
Brain lipids are subject to natural and physiological inﬂuences
uch as age, sex, sleep, but are also inﬂuenced by disease processes
uch as HIV dementia, Huntington’s disease, Alzheimer’s disease
AD), or schizophrenia (Pettegrew et al., 1991; Gattaz et al., 1996;
ulder et al., 1998; Yao et al., 2000; Han et al., 2002; Haughey et al.,
004; Desplats et al., 2007). Regardless of physiological ﬂuctuations
r disease processes, the lipids in the brain can be actively manip-
lated. Small molecules, such as drugs that cross the blood-brain
arrier may  alter the lipid metabolism in the brain. These include
unctional inhibitors of acid sphingomyelinase (Kornhuber et al.,
010), phospholipidosis-inducing drugs (Mühlbacher et al., 2012),
nhibitors of fatty acid synthase (Loftus et al., 2000), or inhibitors of
-hydroxy-3-methylglutaryl-coenzyme A reductase (statins; Botti
t al., 1991; Fassbender et al., 2002; Locatelli et al., 2002). Another
ay to manipulate brain lipids is the intravenous or intracisternal
dministration of lipid metabolizing enzymes (enzyme replace-
ent therapy), which is used primarily in the treatment of lipid
torage diseases. Dietary intake of speciﬁc fatty acids, notably n-3
olyunsaturated fatty acids (PUFAs), also alters the levels of certain
ipids in the brain and can affect human brain function, as measured
y indirect parameters (Eilander et al., 2007). Taken together, brain
ipids can be targeted by drugs, enzyme replacement therapy, gene
herapy, or dietary manipulations; however, most data on these
pproaches come from preclinical studies. Data on the effects of
hese treatments in humans is still limited and further studies are
eeded.
.2.1. Fatty acids and phospholipids
Polyunsaturated fatty acids are fatty acids containing multiple
ouble bonds. Long chain PUFAs, which are more than 20 carbons in
ength, are derived from two independent and nutritionally essen-
ial fatty acids (EFA), -linolenic acid (18:3n-3) and linoleic acid
18:2n-6; Fig. 1). The n-3 or n-6 designation (or omega-3 or omega-
) indicates the presence of double bond at the third or sixth carbon
ond, respectively, from the methyl end of the hydrocarbon chain.
ammals cannot introduce a double bond in the n-3 or n-6 posi-Please cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
ion of the fatty acid chain, and thus, must obtain -linolenic acid
nd linoleic acid from the diet. However, mammals can elongate
he EFAs into biologically important n-3 and n-6 PUFAs such as
icosapentaenoic acid (EPA; 20:5n-3), docosahexaenoic acid (DHA; PRESS
havioral Reviews xxx (2016) xxx–xxx 3
22:6n-3), and arachidonic acid (20:4n-6). The relative abundance of
these PUFA depends on the dietary intake of the EFAs or the PUFAs
themselves (Fenton et al., 1999; Nakamura et al., 2001).
Long chain PUFAs, as well as other fatty acids, are components
of the phospholipids that form the membranes of all cells, includ-
ing neurons. Within the membrane lipid bilayer, phospholipids
that contain PUFAs are preferentially localized around membrane
proteins (Fenton et al., 1999; Uauy et al., 2000). As such, varia-
tion in the PUFA composition of synaptic membranes alters the
microenvironment, and thus structure and function, of membrane-
bound proteins such as receptors and ion channels (Salem et al.,
2001), and thus affects neuronal function. N-3 and n-6 PUFAs can
also be cleaved from the cell membrane by phospholipases, such
as phospholipase A2. Free fatty acids modulate gene expression
at the transcriptional level through the activation of transcrip-
tion factors (e.g., PPAR, LXR, and RXR) (Khan and Van den Heuvel,
2003), and can also be metabolized into inter- and intracellu-
lar signalling substances, such as prostaglandins, thromboxanes,
resolvins, maresins, and protectins (Bannenberg, 2010; Bazan,
2005; Horrocks and Farooqui, 2004; Salem et al., 2001; Serhan and
Petasis, 2011).
In animal models, the most common method of manipulating
the relative amounts of n-3 and n-6 PUFAs in brain phospholipids,
as well as the concentrations of free fatty acids, is by altering the
n-3 and n-6 PUFA content of the diet. A diet low in -linolenic
acid (ALA; 18:3n-3), the essential fatty acid precursor of DHA,
results in decreased concentrations of DHA in brain phospholipids
accompanied by increased incorporation of the 22-carbon n-6 PUFA
docosapentaenoic acid (DPA; 22:5n-6; Favreliere et al., 1998; Galli
et al., 1971). Increased levels of arachidonic acid (AA; 20:4n-6) are
also sometimes reported after treatment with n-3 PUFA-deﬁcient
diets (Bondi et al., 2014; McNamara et al., 2008a,b). Alternatively,
diets high in DHA increase phospholipid DHA content in the brain
(Barcelo-Coblijn et al., 2003; Favreliere et al., 2003). The duration of
treatment required to signiﬁcantly alter brain phospholipid com-
position depends on the developmental stage of the animal. For
example, because DHA accumulates in the brain primarily dur-
ing the late prenatal and early postnatal periods (Clandinin et al.,
1980a,b; Green and Yavin, 1996), dietary manipulations of the preg-
nant and nursing dam or the neonate can readily alter fatty acid
composition of brain phospholipids of the pups. In contrast, once
DHA has accumulated in the brain, the composition of brain phos-
pholipids tends to remain fairly consistent. Accordingly, feeding
adult male rats an n-3 PUFA-deﬁcient diet for 7 months did not
decrease brain DHA content (Bourre et al., 1992). However, stud-
ies in adult female rats and adult male mice have since shown that
diets low in n-3 PUFAs can decrease in the percentage of DHA of
the adult brain, but very slowly. This is consistent with rate of fatty
acid turnover in that tissue, which is normally slow and decreases
further under conditions of low n-3 PUFA availability (DeMar et al.,
2004; Levant et al., 2006b; McNamara et al., 2008a,b).
A less common approach to manipulating brain phospholipid
and free PUFA composition experimentally is the use of transgenic
animals, such as the fat-1 mouse that express C. elegans fat-1, an
enzyme capable of metabolizing n-6 PUFAs into n-3 PUFAs (Kang
et al., 2004). Using this approach, feeding an n-3 PUFA-deﬁcient
diet to fat-1 and control mice resulted in animals with and without
adequate n-3 PUFAs.
Physiological processes can also change tissue phospholipid
fatty acid composition. Most notably, the delivery of DHA to the
developing foetus and neonate during pregnancy and lactation
results in dramatic decreases in the DHA content of the maternaltric disorders and preventive medicine. Neurosci. Biobehav. Rev.
liver and erythrocytes, even when the dam is fed a presumably ade-
quate diet (Levant et al., 2006b, 2007). Brain PUFA composition does
not change if the dam is fed an adequate diet. However, when the
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iet contains inadequate n-3 PUFAs, diet and physiological status
nteract to decrease brain DHA rapidly (Levant et al., 2006b,d).
.2.2. Sphingolipids
Mammalian cell membranes are predominantly composed of
phingolipids, cholesterol and (glycero)phospholipids. In 1972,
inger and Nicolson suggested the ﬂuid mosaic model of the cell
embrane based on biophysical experiments measuring the melt-
ng temperatures of lipids in biological membranes. This model
redicted that lipids are present in the membrane in a liquid dis-
rdered phase with free movement of proteins in the lipid bilayer
Singer and Nicolson, 1972). This view has changed in the last 20
ears: In particular sphingolipids and cholesterol do not seem to
e randomly distributed in the membrane. Sphingolipids are com-
osed of a hydrophilic head group and a hydrophobic ceramide
olecule. Ceramides are composed of d-erythro-sphingosine and
 fatty acid containing 2–36 carbon atoms in the acyl chain (C2–C36
eramide species; Sandhoff, 2010). The amino alcohol and the fatty
cid form an amide ester. Sphingolipids tend to interact with each
ther through interactions of the hydrophilic sphingolipid head
roups (Simons and Ikonen, 1997; Harder and Simons, 1997; Brown
nd London, 1998; Xu et al., 2001; London and London, 2004;
egha et al., 2006). However, since the head groups are rather
ulky, these interactions need to be coordinated in order to pre-
ent steric hindering. This coordination is mediated by cholesterol,
hich interacts with sphingolipids, particularly the most abun-
ant sphingolipid sphingomyelin, via hydrophobic van der Waal
nteractions of its sterol ring with the ceramide part of sphin-
olipids, as well as hydrogen bonds of the hydroxy-group in the
holesterol molecule with the polar head group of sphingolipids
Brown and London, 1998; Xu et al., 2001; London and London,
004; Megha et al., 2006). The coordinated interaction of sphin-
olipids with cholesterol results in an ordered membrane structure
ith cholesterol ﬁlling the voids between the bulky sphingolipids.
ue to the tight interactions between sphingolipids and choles-
erol, stable domains are formed that exist in a liquid-ordered- or
ven gel-like phase (Simons and Ikonen, 1997; Harder and Simons,
997; Brown and London, 1998; Xu et al., 2001; London and London,
004; Megha et al., 2006). These domains spontaneously separate
rom other phospholipids in the cell membrane. Since they ﬂoatPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
n the membrane, these very small domains were named lipid
afts (Simons and Ikonen, 1997). The introduction of these lipid
afts in the concept of membrane composition indicates a lateral
rganization of the cell membrane. A microscopy study conﬁrmeds for polyunsaturated fatty acids (PUFAs).
the existence of small membrane rafts with a diameter of 20 nm
(Eggeling et al., 2009). It should be noted that lipid rafts were only
demonstrated in the outer leaﬂet of the plasma membrane, while it
is unknown whether lipid rafts or similar membrane domains exist
in the inner/cytoplasmic leaﬂet of the plasma membrane.
Sphingomyelin can be hydrolyzed to ceramide (Fig. 2). The
generation of ceramide within lipid rafts, or in general in the mem-
brane (even outside of rafts), dramatically alters the biophysical
properties of the plasma membrane and presumably also intra-
cellular membrane: Ceramide molecules have the tendency to
spontaneously self-associate, a process that results in the forma-
tion of ceramide-enriched membrane microdomains that further
fuse to large ceramide-enriched macrodomains, which can be
easily detected by ﬂuorescence microscopy (Veiga et al., 1999;
Holopainen et al., 1998; Grassmé et al., 2001a). It is very likely
that these domains exist in a gel-like phase, are very hydropho-
bic, and also alter the diameter of the membrane. Ceramide
molecules within these domains appear to be tightly packed and,
therefore, seem to stabilize lipid rafts (Xu et al., 2001; London
and London, 2004). Ceramide-enriched membrane platforms were
visualized by confocal microscopy in vivo in non-ﬁxed cells or
after ﬁxation using ﬂuorescent-labelled anti-ceramide antibodies
(Grassmé et al., 2001a,b, 2002a,b; Dumitru and Gulbins, 2006;
Abdel Shakor et al., 2004; Lacour et al., 2004; Fanzo et al., 2003).
Further biophysical studies were able to follow the formation of
ceramide-enriched membrane macrodomains on line by treatment
of phosphatidylcholine/sphingomyelin-unilamellar vesicles with
sphingomyelinase immobilized onto a microbead and applied via a
glass pipette to the surface of the vesicle (Holopainen et al., 1998).
The generation of ceramide within extracellularly-oriented lipid
rafts/membrane domains, i.e. in the outer leaﬂet of the plasma
membrane on the cell surface, is mediated by the enzyme acid
sphingomyelinase (ASM; Grassmé et al., 2001a), which belongs to
the family of sphingomyelinases that hydrolyse sphingomyelin to
ceramide (Henry et al., 2013). Depending on the optimal pH for
enzyme activity, an acid and several neutral and alkaline sphin-
gomyelinase have been identiﬁed (Henry et al., 2013). Ceramide
can be also generated in membranes de novo by ceramide syn-
thases, which also determine the chain length of the fatty acid
in the ceramide molecule (Tidhar and Futerman, 2013). In addi-atric disorders and preventive medicine. Neurosci. Biobehav. Rev.
tion, ceramide can be generated by hydrolysis of glycosylated
sphingolipids (Ishibashi et al., 2007) and retrograde activity of the
enzyme ceramidase triggering the formation of ceramide from sph-
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Fig. 2. Major sphingolipid synthesis and degradation pathways. Sphingolipid de novo synthesis utilizes the condensation of the activated fatty acid palmitoyl-CoA with
the  amino acid serine. This is catalyzed by serine palmitoyl transferase. The sphingolipid, 3-ketosphinganine (or 3-dehydrosphinganine), which is generated by the de novo
pathway, is converted to sphinganine, dihydroceramide, and ﬁnally ceramide by three consecutive metabolic steps. These steps use the enzymes 3-ketosphinganine reductase,
dihydroceramide synthase/ceramide synthase and dihydroceramide desaturase, respectively. The central molecule of the sphingolipid pathway is ceramide. Ceramide also
serves  for the generation of higher order sphingolipids such as sphingomyelin or glycosphingolipids. These sphingolipids are essential components of the cellular plasma
membrane. If ceramide is n not used as a structural component, it can either be phosphorylated using ceramide kinase to form ceramide-1-phosphate (not shown), or using
ceramidases hydrolyzed to sphingosine. Sphingosine can be phosphorylated to sphingosine-1-phosphate (S1P) by one of two sphingosine kinases. Most of the enzymatic
s ide is 
r and he
o ber e
i
t
c
e
a
P
g
a
2
e
(
i
Z
p
e
e
i
s
d
b
w
d
t
e
D
c
m
v
t
dteps  in the sphingolipid metabolism are reversible. In a salvage pathway, ceram
ecycling of sphingosine or S1P. S1P lyase cleaves S1P into ethanolamine phosphate 
f  the sphingolipid metabolism (modiﬁed from: Lahiri and Futerman, 2007; Kornhu
ngosine (Sph; Okino et al., 2003), although it is unknown whether
hese pathways are active in lipid rafts (Fig. 2).
Our and other’s ﬁndings demonstrate that ASM is activated and
eramide release is triggered by stimulation via CD95 (Grassmé
t al., 2001a,b), CD40 (Grassmé et al., 2002a), DR5 (Dumitru
nd Gulbins, 2006), FcRII (Abdel Shakor et al., 2004), the
AF-receptor (Goggel et al., 2004), CD14 (Pfeiffer et al., 2001), inte-
rins (Carpinteiro et al., 2015); after infection with Pseudomonas
eruginosa (Grassmé et al., 2003), Staphylococcus aureus (Esen et al.,
001), Neisseria gonorrhoeae and Neisseria meningitidis (Grassmé
t al., 1997; Hauck et al., 2000; Simonis et al., 2014), rhinovirus
Grassmé et al., 2005); application of stress stimuli such as -
rradiation (Santana et al., 1996), UV-light (Charruyer et al., 2005;
hang et al., 2001; Rotolo et al., 2005; Kashkar et al., 2005), cis-
latin (Lacour et al., 2004) or Cu2+-treatment (Lang et al., 2007); and
ven in some conditions of developmental death (Scheel-Toellner
t al., 2004). It is surprising that a simple change of the biophys-
cal properties of the plasma membrane seems to be involved in
uch a variety of signalling pathways that have at least partially
ifferent biological effects. This general function of ceramide might
e explained by the phenomenon of receptor trapping/clustering
ithin ceramide-enriched membrane domains. It was previously
emonstrated that stimulation of CD95, DR5 or CD40 induces a
rapping and clustering of the receptor molecules in ceramide-
nriched membrane platforms (Grassmé et al., 2001a,b, 2002a;
umitru and Gulbins, 2006). The generation of a very high con-
entration of a receptor within a small domain of the plasma
embrane seems to be prerequisite for transmembrane signallingPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
ia the clustered receptors (Gulbins and Kolesnick, 2003). Clus-
ering of receptors may  not only result in a very high receptor
ensity, but also a novel spatial distribution of the receptor in therapidly generated via the breakdown of complex membrane sphingolipids or by
xadecenal, two non-sphingolipid molecules. They deﬁne the irreversible exit point
t al., 2014).
plasma membrane. It may  also facilitate association of activated
receptors with downstream signalling molecules and transactiva-
tion of enzymes associating with the activated receptor, exclude
inhibitory molecules, and stabilize the interaction of the cognate
receptor with its ligand. Thus, ceramide-enriched membrane plat-
forms may  have a very general function in signal transduction, i.e.
the re-organization of receptors and signalling molecules in and at
the cell membrane to facilitate and amplify signalling processes via
a speciﬁc receptor.
Utilizing the observation that CD40 clusters in ceramide-
enriched membrane domains while CD45 does not, chimeric
constructs of CD40 and CD45 have been used to study the molec-
ular mechanisms that mediate receptor clustering, (Cheng et al.,
1999). These studies revealed that the transmembrane domain of
CD40 determines receptor clustering, however, molecular details
still require deﬁnition (Bock and Gulbins, 2003).
Sphingolipids are present in all eukaryotic cells and can there-
fore serve as bioactive food components (Vesper et al., 1999).
Cellular sphingolipid metabolism and action can be altered by
dietary sphingolipids, but also by other food components. In mice,
a high fat diet leads to increased ceramide levels and enhanced
ASM or neutral sphingomyelinase (NSM) expression and activ-
ity in plasma, adipose tissue, liver, and the hypothalamus (Boini
et al., 2010; Chocian et al., 2010; Borg et al., 2012). Furthermore,
free fatty acids increase ceramide formation in cultured pancre-
atic cells (Shimabukuro et al., 1998). Dietary intake of n-3 PUFAs
reduces the production of ceramide in splenic lymphocyte cultures
(Jolly et al., 1997) and in the skeletal muscle of mice (Lanza et al.,tric disorders and preventive medicine. Neurosci. Biobehav. Rev.
2013), and also reduces hippocampal ceramide levels (Babenko and
Semenova, 2010). Consistent with these preclinical observations,
randomized control studies in humans also found that enhanced
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ietary levels of n-3 PUFAs reduced ceramide levels in the serum
nd muscle (Lankinen et al., 2009; Kien et al., 2013).
There is a complex link between cholesterol, sphingolipid
etabolism, and function. In rats, a cholesterol rich diet increases
eramide abundance in the plasma and adipose tissue (Ichi et al.,
007). This diet results in accumulation of cholesterol, sphin-
omyelin, and galactosylceramide (GalCer) and increases lipid
eroxidation products in the hippocampus (Stranahan et al., 2011).
oy protein consumption can reduce the ceramide content of the
eart, probably by reducing the expression of serine palmitoyl
ransferase1 (SPT-1), a key enzyme in the formation of ceramide
Torre-Villalvazo et al., 2009). Alcohol enhances the activity of ASM
nd results in increased ceramide levels in cell culture (Pascual
t al., 2003; Saito et al., 2005), rodent models (Saito et al., 2010;
iangpunsakul et al., 2012), and humans (Reichel et al., 2010;
eichel et al., 2011).
There have been mixed results with the effects of physical activ-
ty on tissue ceramide abundance in rodents (Dobrzyn et al., 2004;
elge et al., 2004; Baranowski et al., 2008; Blachnio-Zabielska et al.,
008; Tsalouhidou et al., 2009; Jung and Kang, 2010; Borg et al.,
012). A randomized control study found decreased skeletal muscle
eramide levels after exercise in humans (Dube et al., 2011).
Ageing is associated with changes in brain sphingolipid levels
nd catabolic enzyme activity. A decline in sphingomyelin lev-
ls in the hippocampus of aging rats was reported by Babenko
nd Semenova (2010). A recent study, however, did not ﬁnd
geing-associated changes in sphingomyelin species in the hip-
ocampus and cerebellum of rats (Huston et al., 2016); however,
otal ceramide levels were reduced in aged animals, speciﬁcally in
he dorsal hippocampus. Aged animals also exhibited signiﬁcantly
igher ASM activity in this brain area and in the cerebellum com-
ared to adult rats (Huston et al., 2016), similar to ﬁndings from
hole brain homogenates (Sacket et al., 2009). In rats, increased
ge was associated with enhanced NSM, but not ASM activity
nd subsequent ceramide accumulation in the brain (Babenko
nd Shakhova, 2014; Huston et al., 2016). Caloric restriction or
reatment with N-acetylcysteine or -tocopherol acetate reduced
SM activity and hippocampal ceramide content (Babenko and
hakhova, 2014). No age effects were found on acid ceramidase
AC) or neutral ceramidase (NC) activity in the hippocampus and
erebellum. However, another study found an in increase in both
nzyme activities during aging in whole brain homogenates (Sacket
t al., 2009).
The exact role of diet in brain sphingolipid metabolism and
eramide abundance is not completely understood. From the lim-
ted information available, a healthy lifestyle with a diet high in n-3
UFAs and antioxidants, and low in free fatty acids, cholesterol (e.g.,
he Mediterranean diet), and physical activity might contribute to
 reduced ceramide load (Bergouignan et al., 2009); however, the
ffects of lifestyle on ceramide load have been investigated in only
 few randomized control studies in humans (Lankinen et al., 2009;
ube et al., 2011; Kien et al., 2013).
.2.3. Endocannabinoids
The endocannabinoid (eCB) signalling system consists of
he G-protein coupled cannabinoid receptors (CB1R and CB2R),
he two main endogenous ligands N-arachidonoylethanolamide
anandamide, AEA) and 2-arachidonoylglycerol (2-AG), and their
ynthetic and metabolic enzymes. This evolutionarily ancient and
idely distributed neuromodulatory system is crucial for sustain-
ng and restoring homeostasis of neurotransmission in various
ifferent central and peripheral processes. Thus, it participates in aPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
ultitude of neurophysiological processes such as reward-related
ehaviours, pain perception, emotional homeostasis, cognition, or
otor control (Elphick, 2012; Kano et al., 2009). CB1R and CB2R are
lso the main molecular targets for exogenous cannabinoids, such PRESS
havioral Reviews xxx (2016) xxx–xxx
as plant derived phytocannabinoids from Cannabis sativa (e.g. 9-
tetrahydrocannabinol) and hence mediate the pharmacological
effects of cannabis use/abuse. Other compounds that were recently
discussed as putative endogenous ligands include noladin ether
(2-arachidonyl-glyceryl-ether) that binds to and activates CB1R,
virodhamine (O-arachidonoyl-ethanolamine), the ester of arachi-
donic acid and ethanolamine, and the endogenous vanilloid agonist,
N-arachidonoyl-dopamine (NADA), which also exhibits afﬁnity
for CBR in vitro, and ﬁnally N-homo--linolenoylethanolamine
(HEA) and N-docosatetraenoylethanolamine (DEA) (for review
see: Piomelli, 2003; Buczynski and Parsons, 2010). Notably,
the N-acylethanolamines palmitoylethanolamide (PEA) and
oleoylethanolamide (OEA) are receiving increasing interest as
potential endocannabinoids, although they appear not to interact
with the classical CBR (for review see: Buczynski and Parsons,
2010). However, the presence of most of these compounds in intact
tissues is still a matter of debate and their pharmacological activity
and metabolism still needs to be characterized in detail. Therefore,
AEA and 2-AG are still considered the primary endogenous medi-
ators of eCB signalling (Buczynski and Parsons, 2010). Beyond the
role of cannabis use/abuse as a risk factor for the emergence of
major psychiatric disorders, growing evidence implicates alter-
ations in the eCB system – independent from cannabis ingestion
– in the etiology and pathophysiology of various neuropsychiatric
disorders (Leweke and Koethe, 2008; Marco et al., 2011; Rubino
et al., 2015).
The main endogenous ligands of both CBR are the endocannabi-
noids AEA and 2-AG. AEA acts as a partial agonist on both CBRs and
as a full agonist at the vanilloid receptor, TRPV1 (transient recep-
tor potential vanilloid receptor type). 2-AG acts as a full agonist for
CB1R and CB2R (Kano et al., 2009; Castillo et al., 2012). eCBs cannot
be stored in vesicles due to their lipophilic nature. They are syn-
thesized on demand in an activity-dependent manner in response
to elevation of intracellular calcium levels. Both AEA and 2-AG
are derivatives of arachidonic acid and bind with different afﬁni-
ties and efﬁcacies to CB1R and CB2R, where they produce effects
of short duration due to rapid metabolic inactivation. Both eCBs
are rapidly degraded by the two main hydrolytic enzymes, fatty
acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Hence, eCB levels can be manipulated mainly by indirect strategies,
where inhibiting the cellular uptake or intracellular metabolism of
eCBs following their endogenous release increases the interstitial
concentrations of AEA and 2-AG (Pertwee, 2008; Kano et al., 2009;
Pertwee, 2014).
2-AG is synthesized from the hydrolysis of 2-arachidonoyl-
containing diacylglycerols (DAG) by either of two  enzymes known
as sn-1-speciﬁc DAGL  or  (Fig. 3). Notably, studies employing
DAGL- and DAGL knockout mice indicate that the contribution
of DAGL  to 2-AG biosynthesis in the adult brain is much less
signiﬁcant than DAGL  (Iannotti et al., 2016; Elphick 2012). The
mechanisms by which AEA is synthesized in vivo in the brain are not
yet fully understood, although multiple, and potentially interacting,
pathways might be involved. At least three putative biosynthesis
pathways have been suggested so far: 1.) the direct synthesis of
AEA by hydrolysis of N-arachidonoylphosphatidyl-ethanolamines
(NArPE) by N-acylphosphatidylethanolamine-speciﬁc phospholi-
pase D (NAPE-PLD), 2.) by sequential deacylation of NArPE by
the ˇ hydrolase 4 (ABHD4) and hydrolysis of glycerophospho-
ethanolamine by the glycerophosphodiesterase GDE1, and 3.) via a
phospholipase C (PLC)-like enzyme mediated hydrolysis of NArPEs
to phosphoanandamide, followed by dephosphorylated to AEA by a
phosphatase, such as tyrosine phosphatase PTPN22 (Fig. 3). Studiesatric disorders and preventive medicine. Neurosci. Biobehav. Rev.
using knockout mice further indicate that inhibition of one of these
pathways in the brain can potentially be compensated for by the
remaining biosynthesis routes (Iannotti et al., 2016; Elphick 2012;
Blankman and Cravatt, 2013).
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Fig. 3. Major synthesis and degradation pathways for endocannabinoids. (A) At least 3 putative biosynthesis pathways have been suggested for N-arachidonoylethanolamide
(AEA)  biosynthesis: 1.) a direct synthesis by hydrolysis of N-arachidonoylphosphatidyl-ethanolamines (NArPE) by N-acylphosphatidylethanolamine-speciﬁc phospholipase
D  (NAPE-PLD), 2.) a sequential deacylation of NArPE by the ˇ hydrolase 4 (ABHD4) and the hydrolysis of glycerophosphoethanolamine by the glycerophosphodiesterase
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wDE1,  and 3.) via a phospholipase C (PLC)-like enzyme mediated hydrolysis of NA
uch  as tyrosine phosphatase PTPN22. (B) 2-arachidonoylglycerol (2-AG) is synthe
nzymes known as sn-1-speciﬁc DAGL  or  (COX2, cyclooxygenase 2; FAAH, fatty
FAAH is a major metabolizing enzyme of AEA, but can also
etabolise 2-AG. MAGL is thought to be largely, but not exclu-
ively responsible for the metabolism of 2-AG. Notably, both
CBs can also be metabolized to varying extents by other
nzymes (AEA: N-acylethanolamine hydrolysing acid amidase;
-AG: MAG  kinase, ,-hydrolase (ABHD)6 and ABHD12; AEA & 2-
G: cytochrome P450 enzymes, lipoxygenases and cyclooxygenase
COX)-2) (Pertwee, 2014; Kano et al., 2009; Blankman and Cravatt,
013). FAAH inhibitors include irreversible inhibitors such as
RB597 and O-1887 and the reversible inhibitor OL135. In rodents,
RB597 was shown to elevate brain AEA levels without altering
-AG levels. URB597 was, therefore, used to probe AEA-regulated
hysiology in vivo. Additional examples of the many FAAH
nhibitors that have recently been developed include URB532,
RB694, AM374 (palmitylsulphonyl ﬂuoride), N-arachidonoyl
lycine, N-arachidonoyl serotonin, JNJ1661010, CAY10401(13),
M3506, AM5206, ST4070, PF3845, and PF04457845. MAGL
nhibitors include the non-competitive/irreversible inhibitors,
RB602, JZL184 and N-Arachidonoyl maleimide and the reversible
nhibitor, OMDM169. Very recently, a next-generation MAGL
nhibitor (KML29) based on an O-hexaﬂuoroisopropyl carbamate
caffold has been developed that possesses superior selectivity
oward MAGL.
Notably, only dual FAAH/MAGL inhibitors (e.g. JZL195, SA-57)
losely resemble effects that are produced by direct CBR agonists.
nlike JZL195, which displays similar potency toward FAAH, MAGL,
nd ABHD6, SA-57 is considerably more active toward FAAH and
as found to selectively inhibit FAAH at low doses, and to cross-
eact with MAGL and ABHD6 at higher doses in mice. This selectivity
roﬁle allows SA-57 to act simultaneously as a complete FAAH
nhibitor and partial MAGL/ABHD6 inhibitor in vivo (for detailed
eview see: Pertwee, 2014; Blankman and Cravatt, 2013).
Aside from these indirect pharmacological modulations,
nother approach to experimentally manipulate eCB levels in the
rain is the generation of mice with a genetic deletion of FAAH
r MAGL. Generation and characterization of mice bearing tar-
eted disruption of the Faah gene (FAAH(−/−) mice) conﬁrmed
AAH’s role as the principal AEA hydrolase in vivo (Cravatt et al.,Please cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
001). FAAH(−/−) mice are viable, fertile, and largely indistinguish-
ble from wild-type littermates. Brains from FAAH(−/−) mice have
een found to exhibit dramatically elevated (>10-fold) AEA levels,
hile 2-AG levels and CB1R expression remain unchanged (Cravatto phosphoanandamide, followed by dephosphorylation to AEA by a phosphatase,
by hydrolysis of 2-arachidonoyl-containing diacylglycerols (DAG) by either of two
amide hydrolase; MAGL, monoacylglyerol lipase).
et al., 2001; Blankman and Cravatt, 2013). Mouse models bearing
genetic disruption of the Mgll gene (MAGL(−/−) mice) have also
been described (Chanda et al., 2010; Schlosburg et al., 2010). These
animals display dramatic reductions in 2-AG hydrolase activity and
elevations in 2-AG and other MAGs in the brain and many periph-
eral tissues (Blankman and Cravatt, 2013).
3. Lipids in mood and anxiety disorders
3.1. Fatty acids and phospholipids
3.1.1. Preclinical ﬁndings
N-3 PUFAs affect a number of the neurobiological mediators
believed to be involved in the pathophysiology of depression. Find-
ings vary due to the wide range of animals models used, which differ
in the magnitude of the changes in brain phospholipid composition
as well and the point in the lifespan when that change occurred.
Nevertheless, these studies point to the inﬂuence of PUFAs on sys-
tems regulating mood (Müller et al., 2015).
Consistent with the reduced concentrations of serotonin (5-HT)
found postmortem in the brains of depressed patients and indi-
viduals dying by suicide (Beskow et al., 1976; Lloyd et al., 1974;
Shaw et al., 1967), brain levels of 5-HT and its biosynthetic enzyme
tryptophan hydroxylase were lower in animals with diet-induced
decreases in brain DHA content (Levant et al., 2008; McNamara
et al., 2009a, 2010a). Consistent with a role for DHA in the regulation
of 5-HT levels, treatments that increase brain DHA  content resulted
in higher 5-HT concentrations (Carabelli et al., 2014; Sugasini and
Lokesh, 2014; Vines et al., 2012; Vines et al., 2012), and reversed
the reduced 5-HT levels induced by chronic unpredictable mild
stress (Vancassel et al., 2008). In addition, rats with a reduction of
brain DHA levels of about 70% resulting from feeding a n-3 PUFA-
deﬁcient diet for two generations, had higher density of cortical
5-HT2A receptors (Delion et al., 1994, 1996), similar to that observed
postmortem in depressives or individuals dying by suicide (Arango
et al., 1990).
The mesolimbic dopamine system, which when hypofunction-
ing may  contribute to the anhedonia observed in depressiontric disorders and preventive medicine. Neurosci. Biobehav. Rev.
(Nestler and Carlezon, 2006), is also affected by some treatments
that alter brain PUFAs. In agreement with the reduced levels of
D2 dopamine receptors or mRNA in the nucleus accumbens (Nacc)
of depressed women and in several rat models of the disease
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Bjornebekk et al., 2007; Kram et al., 2002; Moses-Kolko et al., 2012;
app et al., 1994; Yaroslavsky et al., 2006), postpartum female rats
ith a 25% decrease in brain DHA content resulting from the com-
ined effects of pregnancy, lactation, and n-3 PUFA-deﬁcient diet,
ad lower densities of D2 receptors in that brain region (Davis et al.,
010).
Manipulations that reduce brain DHA content can produce
hanges in hypothalamic-pituitary-adrenal (HPA) axis function
imilar to the dysregulation of this system in depression (Plotsky
t al., 1998). Notably, postpartum female rats with a 25% decrease
n brain DHA content had elevated stress-induced serum corticos-
erone levels, as well as greater relative increases in corticosterone
ecretion over basal levels, compared to postpartum females with
ormal brain DHA levels (Levant et al., 2008). Conversely, rats fed
iets supplemented with n-3 PUFAs for 2–3 months had lower
lasma corticosterone levels when subjected to acute stressors
Ferraz et al., 2011; Jiang et al., 2012). Augmented stress responses
n n-3 PUFA-deﬁcient animals, and attenuated responses in n-3
UFA supplemented animals, have also been reported in chronic
tress paradigms (Harauma and Moriguchi, 2011; Hennebelle et al.,
012; Mathieu et al., 2008). A recent study suggests that disrup-
ion of glucocorticoid receptor signalling in n-3 PUFA-deﬁciency
ontributes to these effects (Larrieu et al., 2014).
Similar to the reduced levels of hippocampal brain-derived neu-
otrophic factor (BDNF) found in depression (Schmidt et al., 2011),
xpression of BDNF is modulated by treatments that change brain
HA concentrations. In a variety of animal models, treatments that
ecrease brain DHA result in reduced expression, whereas those
hat increase brain DHA result in higher expression (Blondeau
t al., 2009; Cysneiros et al., 2010; Dwivedi et al., 2003; Ferreira
t al., 2013; Karege et al., 2005; Levant et al., 2008; Venna et al.,
009; Vines et al., 2012; Wu et al., 2004). Recent evidence suggests
hat this regulation of BDNF expression involves DNA methyla-
ion (Tyagi et al., 2015). Consistent with those observations, a diet
nriched with DHA increased concentrations of the BDNF signalling
ediators, calmodulin kinase II and activated Akt, pro-BDNF pro-
essing enzymes such as tissue plasminogen activator, and proteins
nvolved of the increases in BDNF induced by antidepressant drugs
uch as cAMP response element binding protein (CREB; Park et al.,
012; Tang et al., 2015a; Wu  et al., 2007).
Animal behaviours relevant to depression are affected by mod-
lation of brain PUFA composition. Most notably, in the majority
f studies, rodents with experimentally-induced increases in brain
HA content exhibited behaviours in tests such as the forced-swim-
est and tail-suspension-test that are similar of those produced by
ntidepressant drugs, whereas treatments that reduce brain DHA
ave the opposite effect (Blondeau et al., 2009; Carabelli et al.,
014; Chen and Su, 2013; DeMar et al., 2006; Ferraz et al., 2011;
uang et al., 2008; Jiang et al., 2012; Laino et al., 2010; Lakhwani
t al., 2007; Moranis et al., 2012; Park et al., 2012; Venna et al.,
009; Vines et al., 2011; Weiser et al., 2015; Wietrzych-Schindler
t al., 2011). In some studies, treatments involving decreased n-
 PUFAs also resulted in anhedonia (Frances et al., 2000; Papp
t al., 1991). Fish oil supplementation reversed depression-like
ehaviours induced by chronic unpredictable mild stress and treat-
ents that induce depression-like behaviour in rodents (Tang et al.,
015b).
Finally, anxiety, which can occur alone or together with depres-
ion, is affected by PUFAs. Rodents fed diets with inadequate n-3
UFA exhibited behaviours consistent with increased anxiety in
ehavioural paradigms such as the open ﬁeld, elevated-plus-maze,
nd the conditioned fear tests (Bondi et al., 2014; Carrie et al., 2000;Please cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
hen and Su, 2011; Takeuchi et al., 2003). Similar effects have been
eported in pigs and primates (Clouard et al., 2015; Pifferi et al.,
015). PRESS
havioral Reviews xxx (2016) xxx–xxx
In addition to ﬁndings showing that manipulations of brain fatty
acids affect neurobiology in ways that may  contribute to mood dis-
orders, preclinical studies also suggest that some drugs used in the
treatment of mood disorders, such as bipolar disorder, may act
through mechanisms involving brain phospholipids. Notably, AA
turnover and expression of cPLA2, the phospholipase selective for
AA, in rat brain were downregulated by clinically-approved drugs
(i.e., lithium and carbamazepine) used as mood stabilizing agents
for bipolar disorder, suggesting a common mechanism of action in
this condition (Rapoport, 2014).
3.1.2. Human ﬁndings
A number of studies suggest a relationship between depressive
symptoms and tissue levels of n-3 PUFAs. Many of the studies of the
PUFA composition in the serum, plasma, or erythrocytes, as well as
a meta-analysis, indicated lower DHA concentrations, or increased
n-6:n-3 PUFA ratio in depression, as well as in anxiety (Assies
et al., 2010; Lin et al., 2010; Lotrich et al., 2013; Marx et al., 2015;
McNamara et al., 2010b, 2014; Pottala et al., 2012; Riemer et al.,
2016; Swenne et al., 2011; Tsuchimine et al., 2015; Verly-Miguel
et al., 2015). Likewise, postmortem examination of the brains of
individuals with depression found lower levels of DHA than in con-
trols in brain regions such as the orbitofrontal cortex and cingulate
cortex (Conklin et al., 2010; McNamara et al., 2007a). DHA levels
were also lower in the prefrontal cortex (PFC) of individuals dying
from suicide (McNamara et al., 2013). In addition, the expression
of genes involved in PUFA biosynthesis, such as FADS1, were lower
in individuals dying from suicide or in patients with depression
(Lalovic et al., 2010; McNamara and Liu, 2011). DNA methylation
in regulatory regions of the elongation of very long-chain fatty acids
protein 5 (Elovl5) was  also associated with major depression and
suicide attempts (Haghighi et al., 2015). Other studies, however
found no relationship between DHA levels in erythrocytes (Parker
et al., 2015; Persons et al., 2014) or in the PFC, entorhinal cortex,
and the amygdala (Lalovic et al., 2007; McNamara et al., 2009a,b;
Hamazaki et al., 2012; Hamazaki et al., 2013; Hamazaki et al., 2015)
with depression or suicide.
Alterations in PUFA status have also been found in bipolar
disorder. Most notably, a postmortem study of brains from individ-
uals with bipolar disorder found decreased concentrations of DHA
(−24%) and AA (−14%) in the orbitofrontal cortex compared to con-
trols (McNamara et al., 2008a,b), though not in the prefrontal cortex
(Hamazaki et al., 2015). Studies of serum, plasma, or erythrocytes
from individuals with bipolar disorder indicate decreased concen-
trations of DHA, as well as altered ratios of fatty acids suggestive
of dysregulated PUFA metabolism (Evans et al., 2014; McNamara
et al., 2015). Another study in erythrocytes found decreased levels
of both DHA and AA in bipolar patients (Chiu et al., 2003). Within
a group of bipolar patients, lower serum AA levels were associated
with prior suicide attempts (Evans et al., 2012). However, erythro-
cyte DHA levels in bipolar patients were not correlated with mania
severity (McNamara et al., 2015), nor did they change as symptoms
improved after treatment with lithium or quetiapine (McNamara
et al., 2016).
A number of clinical trials have examined the effects of vari-
ous n-3 PUFA preparations in depressed patients. Although these
studies have had varying results, most meta-analyses and other
systematic evaluations of this literature support the efﬁcacy of n-
3 PUFAs, particularly EPA or combinations of EPA and DHA, for
depression (Appleton et al., 2010; Bloch and Hannestad, 2012;
Grosso et al., 2014; Lin and Su, 2007; Martins, 2009; Meyer et al.,
2013; Rocha Araujo et al., 2010; Ross et al., 2007; Sublette et al.,atric disorders and preventive medicine. Neurosci. Biobehav. Rev.
2011; Yang et al., 2015, 2016). Furthermore, recent studies sug-
gest that certain sub-populations of depressed patients may  be
more likely to have a beneﬁcial effect from n-3 PUFAs. For example,
subjects with higher levels of inﬂammation showed more improve-
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ent in depression when treated with EPA (Rapaport et al., 2015).
n another study, depressed patients with low DHA levels were
ess likely to respond to treatment with an antidepressant drug
Mocking et al., 2015).
Although fewer studies have been done, clinical trials of n-3
UFAs in bipolar disorder suggest that treatments are well tolerated
nd may  have some efﬁcacy. Controlled, double-blind trials, as well
s several open label studies, in adult and pediatric patients indicate
eneﬁcial effects of n-3 PUFA treatments on depressive, and some-
imes also manic symptoms (Fristad et al., 2015; Osher et al., 2005;
toll et al., 1999; Wozniak et al., 2015). Studies in which n-3 PUFAs
ere administered as an add-on to standard pharmacological treat-
ent also found improved mania and depression scores (Clayton
t al., 2009), or decreased irritability in patients with that symp-
om (Sagduyu et al., 2005). Other studies failed to ﬁnd an effect of
-3 PUFAs in bipolar disorder (Gracious et al., 2010; Murphy et al.,
012); however, metaanalyses support the ﬁnding of improved
epression, though not mania, in these patients (Rosenblat et al.,
016; Sarris et al., 2012).
.2. Sphingolipids
.2.1. Preclinical ﬁndings
Sphingolipids are, together with cholesterol and glycerophos-
holipids, the most abundant lipids in brain membranes (Jackson
t al., 2005, 2007; Jain et al., 2014) where they form physical bar-
iers. But sphingolipids and cholesterol also play an important role
rganizing the neurotransmitter signalling and protein-receptor
ediated signal transduction. Together, they shape the properties
f lipid rafts, which are membrane compartments enriched in G-
rotein-coupled receptors (GPCR; Hering et al., 2003). Lipid rafts
re deﬁned as lateral assemblies within the cell membrane contain-
ng high levels of sphingolipids and cholesterol in tight hydrophobic
nteractions with low levels of glycerophosphocholine (PC; Veiga
t al., 2000, 2001). A privileged binding partner of sphingolipids is
holesterol which interacts through its alpha face with other lipids,
ike sphingomyelins, and through its beta face with transmembrane
roteins, like neurotransmitter receptors. When the composition
f lipid rafts changes, e.g., by decreasing levels of either cholesterol
r sphingomyelin, this may  directly affect receptor afﬁnity, their
ignalling properties, and subsequent internalization (Fantini and
arrantes, 2009; Pike, 2009; Ramstedt and Slotte, 2006; Colon-Saez
nd Yakel, 2011). Lipid rafts are considered to be the predominant
ites where ASM is activated. This activation was  shown to enhance
eramide generation in response to various stressors. Ceramide
hich is highly hydrophobic is concentrated in patches on the
ell surface. These patches may  rapidly merge to larger platforms
r macrodomains and anchor a multitude of membrane-proteins,
uch as protein kinase C or c-Raf-1, to a speciﬁc site. This alloca-
ion may  enhance oligomerization of speciﬁc cell surface proteins
ncluding GPCRs (Kolesnick et al., 2000; Cremesti et al., 2002).
Depression-like behaviour can be induced in rodents by the
ryptophan hydroxylase inhibitor p-chlorophenylalanine (pCPA).
 lipidomic analysis revealed that pCPA treatment led to a dys-
egulation of several lipid species, including sphingolipids, in
ice. Sphingomyelin, GalCer, glucotosylceramide (GluCer), and
actosylceramide (LacCer) were downregulated, whereas PC and
hosphatidylinositol (PI) were upregulated in pCPA treated ani-
als (Weng et al., 2015). A recent study in rats demonstrated that
npredictable stress for several weeks can lead to an increase in
eramide levels in the PFC and hippocampus. Sphingomyelin lev-
ls, in contrast, were decreased. In this study, serum corticosteronePlease cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
evels appeared to be negatively correlated with PFC sphingomyelin
evels (Oliveira et al., 2016). Interestingly, no signiﬁcant effects
ere observed in the amygdala or cerebellum (Oliveira et al., 2016;
iranda and Oliveira, 2015). Chronic stress can induce depression PRESS
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if adequate coping does not develop. However, when coping devel-
ops, an aversive emotional reaction emerges, as well as learning of
how to adapt to the stress. An example of this type of situation is
when a well-established rewarded behaviour is no longer rewarded
(Scully et al., 2000). This usually leads to an extinction of the
behaviour, which is an active re-learning of the reinforcement con-
tingency rather than passive forgetting (Quirk and Mueller, 2008;
Todd et al., 2014), and is accompanied by an aversive emotional
reaction, which may  resemble a short depressive state (Papini
2003; Huston et al., 2013). Huston et al. have shown that extinction
learning is paralleled by a decline in total ceramide, but not sphin-
gomyelin levels in the dorsal hippocampus and cerebellum, but not
in the ventral hippocampus of rats (Huston et al., 2016). This effect
was probably mediated by a decline in local ASM, but not NSM activ-
ity. Interestingly, the degree of re-learning during extinction was
associated with the change in ASM activity: the stronger the decline
in ASM activity, the more efﬁciently re-learning occurred (Huston
et al., 2016). A reduction in ceramide levels, as it was observed after
knocking out carnitine palmitoyltransferase 1C (CPT1C) in mice,
was associated with increased ﬁlopodia density and reduced spine
maturation in hippocampal neurons as well as with impaired learn-
ing of a spatial memory task in the Morris water maze (Carrasco
et al., 2012). However, in this model, a ceramide-independent role
of CPT1C may  also contribute to the observed effects. Altogether,
these ﬁndings suggest a highly dynamic and brain area-speciﬁc
homoeostasis of sphingolipid levels in the brain that is tightly reg-
ulated by catabolic and metabolic enzymes. This homeostasis is
responsive to normal learning and stress, and potentially involved
in rapid behavioural adaptations (Gulbins et al., 2015).
The role of sphingolipids in depression/anxiety was investigated
in animal studies using genetically modiﬁed mice to manipulate
the relevant anabolic and catabolic enzymes. Mice deﬁcient in
ASM (ASM KO) typically develop Niemann-Pick disease, a lyso-
somal storage disorder, in late adulthood. Heterozygous ASM KO
did not show the disease phenotype. Nevertheless, the ASM KO
mice had reduced ceramide levels in the hippocampus and reduced
anxiety and depression-like behaviours. ASM over-expressing mice
(tgASM) showed higher ASM activity and ceramide production in
the hippocampus (Gulbins et al., 2013). Increased ceramide lev-
els in the hippocampus resulted in reduced levels of neurogenesis,
neuronal maturation, and neuronal survival (Gulbins et al., 2013),
which is associated with a depression-like behavioural phenotype
(Santarelli et al., 2003; Krishnan and Nestler, 2008; Gulbins et al.,
2015). Consistent with these observations, tgASM mice showed a
depression/anxiety-like phenotype in several tests including the
novelty-suppressed-feeding test, the splash-test, open ﬁeld, light-
dark-box, and forced-swim test (Gulbins et al., 2013; for a review,
see: Kornhuber et al., 2014).
Hippocampal neurogenesis is controlled by Akt phosphory-
lation (Zundel and Giaccia, 1998). In tgASM mice, a reduction
in Akt phosphorylation at Ser473 was observed (Gulbins et al.,
2013). The inhibitory action of C16 ceramide on cell proliferation
could be prevented in PC12 cells by a T308DS473Akt1 mutation
(Gulbins et al., 2013). Furthermore, corticosterone-stress reduced
hippocampal neurogenesis by activation of p38-kinase by an ASM
activation-dependent mechanism (Grassmé et al., 2015; Jernigan
et al., 2015). Ceramide hypo- or hyperfunction, when genetically
induced, had no gross effects on synaptic structure or function
in the hippocampus (Gulbins et al., 2013). Antidepressant drugs,
many of which appear to be functional inhibitors of ASM (Albouz
et al., 1986; Kornhuber et al., 2010, 2011), reversed the effects of
chronic unpredictable stress on behaviour in wild type and tgASMtric disorders and preventive medicine. Neurosci. Biobehav. Rev.
animals, but not in ASM KO mice. A pharmacological inhibition
of ASM with tricyclodecan-9-yl-xanthogenate reduced interferon-
 (IFN)-induced 5-HT uptake in T-cells (Su et al., 2011). These
ﬁndings suggest that ASM is a functional requirement for antide-
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ressant action in the brain (Gulbins et al., 2013; Kornhuber et al.,
014; Müller et al., 2015).
While ASM exhibits maximal activity in an acidic milieu, there
s also a sphingomyelinase that prefers a neutral pH range: the
SM. The pharmacological inhibition of neutral sphingomyelinase
 (NSM2) with GW4869 reduced the levels of multiple ceramide
pecies in the brain. Inhibition of NSM2 in mice had little effect
n episodic memory, but impaired spatial reference memory,
nd changed N-methyl-d-aspartate (NMDA) and alpha-amino-
-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor
ubunit composition and the membrane insertion of these recep-
ors (Wheeler et al., 2009). In contrast, higher ceramide levels,
esulting from NSM activity, resulted in increased action potential
requency and reduced slow after-hyperpolarization in hippocam-
al slice preparations (Norman et al., 2010), effects associated with
mproved information processing. Pharmacological inhibition of
SM with sphingolactone-24 in T-cells in vitro showed a reduced
FN − induced 5-HT uptake (Su et al., 2011). These ﬁndings may
uggest that NSM inhibition has an antidepressant effect.
Ceramide in the brain is metabolized by AC. However,
epression-like behaviour of rats in the forced-swim test was not
ffected by pharmacological inhibition of AC with LCL385 (Nahas
t al., 2009). In contrast, increased depression-like behaviour was
ound in AC heterozygous KO mice, which was accompanied by
educed neuroneogenesis, neuronal maturation, and neuronal sur-
ival (Gulbins et al., 2013).
Ceramide is hydrolyzed by ceramidases to Sph. Sph can be re-
cylated by ceramide synthases (CerS). Six different CerSs have
een described in mammals so far. A spontaneous deﬁciency in
erS1 activity was identiﬁed in lincher mice, which have reduced
otal brain ceramide and C18- levels, but increased C16 ceramide
evels, and exhibit cerebellar and motor dysfunction (Zhao et al.,
011). In contrast, a genetic deletion of CerS1 function decreased
18 ceramide levels in the cerebellum and increased C16- and C22
eramide levels, but with no net change in total ceramide level.
hese effects were associated with attenuated locomotor activity
nd impaired motor learning, as well as reduced anxiety in the open
eld test and spatial working memory deﬁcits (Ginkel et al., 2012).
n another study, a genetically-induced deﬁciency in CerS6 led to
ower C16 ceramide levels in the thymus, small intestine, and kid-
ey of mice. Only a small decrease in C18 ceramide was  observed
n the cerebellum of these mice, and no ceramide alterations were
etected in the forebrain. CerS6 KO mice were hyperactive in a
ovel environment, but did not display altered levels of anxiety-
elated behaviour or changes in novel object recognition (Ebel
t al., 2013). These ﬁndings suggest that ceramide is not only
nvolved in affective behaviour, but also controls locomotor activity
nd cognition. Consistent with these ﬁndings, repeated injections
f C16 ceramide into the dorsal hippocampus of mice produced
epression-like behaviour in the novelty-suppressed-feeding and
ucrose-preference tests (Gulbins et al., 2013). Likewise, ceramide
pplication in hippocampal slices depressed long-term synaptic
esponses, an effect mediated by ionotropic glutamate receptors
Vines et al., 2012).
Finally, chronic unpredictable stress, which induces depression-
ike behaviour, increased hippocampal ceramide levels and
educed neuroneogenesis and neuronal maturation in mice
Gulbins et al., 2013).
Evidence also suggests that the mechanism of action of antide-
ressant drugs may  be mediated, at least in part, through effect of
phingolipids. A lipidomic study suggested that a daily i.p. treat-
ent with the antidepressant drugs maprotiline or paroxetinePlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
educed sphingomyelin species and increased ceramide species,
lthough ﬂuoxetine, maprotiline, or paroxetine had no signiﬁcant
ffects on the hippocampal levels of ceramide or sphingomyelin
Lee et al., 2009). These ﬁndings suggest that the antidepressant PRESS
havioral Reviews xxx (2016) xxx–xxx
action of a pharmacological treatment may  not involve reducing
hippocampal ceramide content; however, this study was con-
ducted in normal mice that had normal basal ceramide levels, thus
limiting interpretation of the data to healthy organisms.
In addition to the involvement of sphingolipids in depressive
neurochemistry and behaviour, these lipids are also implicated in
anxiety. In an early life stress model, mice subjected to stress during
early weaning had signiﬁcant increases in GalCer in the amygdala,
though not in the hippocampus or PFC, at 5 weeks of age. GalCer
is a major component of the myelin sheath in the brain. The rise
in GalCer was paralleled by an increase in anxiety-like behaviour
in the elevated-plus-maze test at 5 and 8 weeks of age, suggesting
that GalCer in the amygdala may  be an important mechanism for
the establishment of a hyperanxious phenotype (Ono et al., 2008).
Sphingosine kinases phosphorylate Sph, which is derived from
ceramide hydrolysis, to sphingosine-1-phosphate (S1P; Lahiri
and Futerman, 2007; Kornhuber et al., 2014). S1P can interact
with ﬁve different G-protein-coupled receptors: S1P(1)–S1P(5).
S1P(2) receptors are exclusively found in hippocampal pyrami-
dal/granular neurons. Mice lacking the S1P(2) receptor (S1P(2)−/−)
displayed a high rate of spontaneous seizures and cognitive deﬁcits
as well as an increase in anxiety-related behaviour (Akahoshi et al.,
2011). Restraint stress, which increases anxious behaviour in rats,
enhanced serum levels of S1P and sphinganine-1-phosphate. How-
ever, it had no effects on Sph or sphinganine levels (Jang et al.,
2008, 2011). S1P is known to induce neurogenesis in the brain
(Anderson and Maes, 2014), which is required for effective cop-
ing with new stressors (Snyder et al., 2011) and for the effects of
antidepressant drugs (Santarelli et al., 2003). Thus, an increase in
S1P was suggested to play a causal role in stress-induced anxiety
and depression. This is supported by ﬁndings showing increased
anxiety-related behaviour after local infusion of S1P into the cere-
bral ventricles for 7 days via osmotic mini-pumps. S1P in the brain
led to a selective decrease in tyrosine hydroxylase expression
in the amygdala, but not in the cortex. Likewise, expression of
extracellular-signal regulated kinase (ERK) and phosphoERK, post-
synaptic markers for dopaminergic activity, were not signiﬁcantly
affected (Jang et al., 2011). These ﬁndings support the view that
stress can cause an increase in S1P levels in speciﬁc brain areas,
which promotes anxiety-related behaviour.
Another likely mediator of sphingolipid’s role in anxiety is sph-
ingosine kinase 2 (SphK2). Mice lacking SphK2 (SphK2−/−) express
signiﬁcantly less S1P and dihydro-S1P in the hippocampus. Ini-
tial fear responses and the acquisition of contextual fear were
not altered in SpHK2−/− mice; however, they exhibit signiﬁcantly
impaired extinction of fear memory. Thus, while not required for
fear-conditioning, S1P appears to be necessary for the extinction of
conditioned fear (Hait et al., 2014).
In conclusion, preclinical studies suggest a direct control of
depression/anxiety-related behaviour by sphingolipids and their
regulatory enzymes in the brain (Müller et al., 2015). Initial ﬁnd-
ings suggest that this is mediated by their effects on monoaminergic
receptor signalling and transmitter synthesis as well as by effects
on neuroneogenesis (Gulbins et al., 2015). However, due to their
abundance and localization in all neurons, an organisational role for
other neurotransmitter systems appears highly likely and awaits
further research.
3.2.2. Human studies
The quantiﬁcation of lipids in human brain tissue provides direct
evidence for the involvement of sphingolipids in mood disorders.atric disorders and preventive medicine. Neurosci. Biobehav. Rev.
Elevated concentrations of ceramide can be found in the white mat-
ter in patients with bipolar disorder (Schwarz et al., 2008). In human
brain tissue, Gs is localized to lipid rafts and other membrane
regions. In patients who have died by suicide, Gs is preferentially
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ound to lipid rafts in the cerebellum and PFC (Donati et al., 2008),
upporting of a role of sphingolipids in depression.
Studies of peripheral tissues also provide indirect evidence
or the involvement of sphingolipids in mood disorders. ASM
ctivity was increased in peripheral blood mononuclear cells of
atients with major depressive disorder (Kornhuber et al., 2005),
lasma ceramide levels were increased in cognitively-impaired
atients with depressive symptoms (Gracia-Garcia et al., 2011), and
ncreased ASM activity and ceramide were observed in the blood
f patients with post-traumatic stress disorder (Hammad et al.,
012) which is often associated with depression. Plasma ceramide
ere also found to correlate with depressive symptoms in patients
ith Parkinson’s disease (Mielke et al., 2013). Finally, altered sph-
ngolipid metabolism was found in conjunction with depressive
ymptoms in a family study (Demirkan et al., 2013). Thus, studies
f peripheral samples consistently link increased activity of ASM
nd/or increased levels of ceramide with a depressive phenotype.
.3. Endocannabinoids
.3.1. Preclinical ﬁndings
The involvement of eCB signalling in the mediation of emotional
ehaviours is very complex and only partially understood. Admin-
stration of cannabinoid agonists in rodents has been reported to
nduce anxiogenic as well as anxiolytic-like responses, depending
n dosage, test paradigm, the test context, test conditions (e.g. light
ntensity; familiar vs. unfamiliar environment), species or genetic
train. Generally, low doses tend to reduce, and high doses tend
o increase, anxiety-like behaviours (for review see: Batista et al.,
014; Moreira and Lutz, 2008; Rubino et al., 2015). Central adminis-
ration of methanandamide, a metabolically stable analogue of AEA,
irectly into the PFC induced anxiolytic-like responses in rats for
ow doses, whereas high doses induced anxiogenic effects (Rubino
t al., 2008). Increasing PFC AEA levels by microinjection of URB597
nduced anxiolytic responses only at low doses, and had no effect,
r even an anxiogenic proﬁle, at higher doses. In line with this,
ecreased AEA levels in the PFC, produced by lentivirus-mediated
ocal overexpression of FAAH, produced an anxiogenic response.
hese ﬁndings support an anxiolytic role for physiological increases
n AEA in the PFC; however, more marked increases or decreases
f this endocannabinoid might lead to an anxiogenic response
Rubino et al., 2008). Less is known about the consequences of
eightened 2-AG signalling on emotional behaviour. Recent stud-
es with the MAGL inhibitor, JZL184, report similar anxiolytic-like
esponses in rodents than for AEA (Blankman and Cravatt, 2013;
ubino et al., 2015). Microinjection studies implicate the amygdala,
entral and dorsal hippocampus, and the dorsal periaqueductal
rey as brain regions directly involved in eCB actions on emotional
ehaviour (Batista et al., 2014).
The eCB system has been suggested to serve as a protective
echanism that is only recruited as needed to restore physiological
omeostasis, like for example counteracting the consequences of
n aversive or stressful stimulus (Batista et al., 2014; Moreira and
utz, 2008). Systemic inhibition of endocannabinoid degradation by
AAH/MAGL inhibitors seems to circumvent the biphasic effects by
nhancing CB1R signalling in a temporally and spatially restricted
anner, thus, reducing anxiety-like behaviours. This might offer
n interesting therapeutic potential. Aside from studies investi-
ating acute anxiolytic responses, various studies have reported
nti-anxiety and antidepressive effects in studies of the effects of
AAH inhibition, mainly by URB597 and PF-3845, and the MAGL
nhibitor, JZL184, in animal models of anxiety and depression, suchPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
s chronic unpredictable stress, forced-swim, and restraint stress
est, (Batista et al., 2014; Fowler, 2015). However, the prepon-
erance of animal data was obtained in studies using only male
odents. Strong sex differences exist in the prevalence for anxi- PRESS
havioral Reviews xxx (2016) xxx–xxx 11
ety and mood disorders, with women being more susceptible to
these disorders (Kokras and Dalla, 2014; Fowler, 2015). In addition,
possible undesired central and peripheral effects of chronic eCB
degradation inhibition remain to be clariﬁed (Batista et al., 2014;
Fowler, 2015). Hence, the translational value of these ﬁndings is
not completely clear.
3.3.2. Human studies
The main features of recreational cannabis use in humans are
euphoric and relaxing effects. However, similar to ﬁndings in ani-
mal  studies, cannabis can also induce dysphoric reactions, including
severe anxiety, panic, and paranoia. The involvement of eCB sig-
nalling in emotional states in humans became most apparent
by the unexpected anxiogenic and depressive effects seen in the
clinical use of the CB1 R antagonist/inverse agonist, rimonabant
(SR141716). Rimonabant was  initially introduced as a weight-
reducing agent, but was  withdrawn from the market shortly after
its release due to the induction and exacerbation of depressive
symptoms and mood alterations. Thus, endogenous activation of
the CB1R may  serve as a buffer against depression; however, the
elimination or reduction of that stimulation can result in depressive
symptoms (Van Gaal et al., 2008; Fowler, 2015; Patel and Hillard,
2009).
To date, there are only few direct investigations of the role of eCB
signalling in patients with mood and anxiety disorders. Alterations
in CB1R expression in postmortem patients with mood disorders
predominantly in cortical areas (Hillard and Liu, 2014). Tissue con-
tents of both AEA and 2-AG in the dorsolateral PFC were increased
in alcoholic patients who  were depressed compared to alcoholics
without depression (Vinod et al., 2005). In addition, ventral striatal
FAAH activity was  higher in alcoholic suicides than in alcoholics
(Vinod et al., 2010), which might indicate lower AEA contents
in subcortical regions. Altogether, postmortem evidence suggests
region-speciﬁc alterations in eCB signalling in depressed individu-
als (Hillard and Liu, 2014).
Peripheral markers of eCB activity are also altered in depression.
Notably, serum 2-AG and AEA concentrations were signiﬁcantly
reduced in depressed women  compared to controls (Hill et al., 2008,
2009). Moreover, 2-AG concentrations were inversely correlated
with the length of the depressive episode (Hill et al., 2008). Based
on these ﬁndings, it has been suggested that assessment of circulat-
ing eCBs may  provide a useful biomarker for depression in general,
but more importantly, could be used in a personalized medicine
approach in which a subgroup of patients with “low eCB” depres-
sion might derive more beneﬁt from an eCB-based therapy (Hillard
and Liu, 2014).
Although, cannabis is typically the most commonly abused drug
in individuals with bipolar disorder, studies addressing a poten-
tial pathophysiological involvement of the eCB system in bipolar
disorder are rare (Leweke and Koethe, 2008; Ashton and Moore,
2011). Postmortem CB1R expression appears to be unaltered in
the anterior cingulate cortex of bipolar patients (Koethe et al.,
2007). Similarly, a ﬁnal conclusion on eCB levels cannot be drawn at
present. One study examining eCB levels reported elevation of AEA
levels exclusively in schizophrenic patients (Giuffrida et al., 2004),
while AEA remained unaltered in patients with dementia or affec-
tive disorder; however, the sample size for the affective disorders
group was only 22 patients comprised of a mixture of individu-
als with depressive or bipolar diagnoses. Mixed results have also
been reported on the involvement of FAAH polymorphisms, indi-tric disorders and preventive medicine. Neurosci. Biobehav. Rev.
cating either minor (Monteleone et al., 2010) or no (Pisanu et al.,
2013) involvement of FAAH SNPs in bipolar disorder, while neither
CNR1 nor NAPE-PLD SNPs were found to be associated with bipolar
disorder (Monteleone et al., 2010; Pisanu et al., 2013).
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.4. Preventive medicine for mood- and anxiety disorders
Changes in lipids have been identiﬁed in patients with major
epressive disorder (Lin et al., 2010). These include lower levels
f EPA, DHA and total n-3 PUFAs, consistent with a phospholipid
ypothesis of depression (Horrobin and Bennet, 1999). Re-analysis
f the prospective randomized PREDIMED study (Estruch et al.,
013) that aimed to prevent cardiovascular events with Mediter-
anean diet, showed reduced depression scores in diabetic patients
Sanchez-Villegas et al., 2013). A systematic review of cohort stud-
es and a meta-analysis show an inverse relationship between
he consumption of n-3 fatty acids and monounsaturated fatty
cids with later-occurring depression (Sanhueza et al., 2013; Li
t al., 2015a,b). This evidence is limited, as it comes from cohort
tudies. However, results of a prospective, randomized controlled
tudy point into the same direction: Mediterranean diet with a
igh content of n-3 fatty acids is associated with lower depres-
ion scores in follow-up studies (Sanchez-Villegas et al., 2013).
urthermore, the consumption of n-3 fatty acid can prevent
nterferon-alpha-induced depression (Su et al., 2014). Long-term
rospective interventions studies aiming to prevent depression and
nxiety via lipid pathways are currently lacking. Therefore, there
re no clear evidence-based recommendations for the prevention
f depression via lipid mechanisms.
In humans, a diet rich in PUFAs reduced ceramide levels in
erum and muscle tissue (Lankinen et al., 2009). Muscle ceramide
as also been found to be reduced after physical exercise (Dube
t al., 2011). Conversely, alcohol dependence is associated with
ncreased peripheral lysosomal and secreted ASM activity (Reichel
t al., 2010, 2011) and higher concentrations of several ceramide
pecies (Reichel et al., 2015). Oxidative stress plays an important
ole in the enzymatic and non-enzymatic metabolism of brain lipids
Assies et al., 2014). Oxidative stress induces the ASM/ceramide sys-
em and is, in turn, induced by the ASM/ceramide system, leading
o a vicious cycle of activation (Kornhuber et al., 2014). Accordingly,
he most deﬁnitive current evidence indicates that a Mediterranean
iet reduces oxidative stress (Dai et al., 2008), where as alcohol
onsumption increases oxidative stress (Bleich et al., 2000). In the
bsence of long-term, high quality prospective studies of lipids
n the prevention of mood disorders, and in the absence of evi-
ence based guidelines, a safe recommendation would therefore
e a healthy lifestyle with physical exercise, a PUFA-rich diet such
s the Mediterranean diet, and the avoidance of excessive alcohol
onsumption.
. Lipids in schizophrenia
.1. Fatty acids and phospholipids in schizophrenia
.1.1. Preclinical ﬁndings
Depending on the speciﬁc manipulation and the point in devel-
pment when it is made, changes in brain phospholipid fatty
cid composition can result in number of neurobiological effects
hat may  be relevant for schizophrenia (Brisch et al., 2014). Most
otably, in adult rats with a 70% reduction of brain DHA content
esulting from multigenerational treatment with an n-3 PUFA-
eﬁcient diet, numerous effects on the dopamine systems were
bserved, many of which are similar to those associated with
chizophrenia (Chalon, 2006). These alterations included decreased
ensities of dopamine-immunoreactive vesicles, of the vesicular
onoamine transporter2 (VMAT2), and the D2 dopamine receptorPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
n frontal cortex suggesting a hypoactivity of the mesocortical pro-
ection (Delion et al., 1996; Zimmer et al., 1999, 2000b). In addition,
asal dopamine release and the density of D2 dopamine recep-
ors in the Nacc and tyrosine hydroxylase activity in the ventral PRESS
havioral Reviews xxx (2016) xxx–xxx
tegmental area (VTA) were increased suggesting hyperactivity of
the mesolimbic system (Zimmer et al., 2000a, 2002). The nigros-
triatal system of these rats, on the other hand, appeared normal
with respect to dopamine content, D1 and D2 receptor density, and
the density of the dopamine transporter (Delion et al., 1996; Kodas
et al., 2002). Another study using a multigenerational treatment
model that reduced the concentration of DHA in brain phos-
pholipids by about 80% found differential effects at adolescence
and adulthood. Adolescent rats exhibited increased expression of
tyrosine hydroxylase in the dorsal striatum, whereas adults had
decreased tyrosine hydroxylase protein levels and increased lev-
els of VAMT2 (Bondi et al., 2014). Studies of single generation
n-3 PUFA deﬁciency during pre- and early postnatal development
found dopaminergic alterations such as decreased levels of tyro-
sine hydroxylase and VMAT2 in the hippocampus, and increased
D1 and D2 receptor levels in the striatum and cortex (Kuperstein
et al., 2005, 2008). However, in adult rats with decreases in brain
DHA of only about 20% induced by feeding a diet with reduced n-3
PUFA content from conception, no alterations in the densities of
D1 or D2 receptors or the concentrations of dopamine in the Nacc,
frontal cortex, or striatum were observed (Levant et al., 2010). This
variability in the neurochemical alterations produced by manip-
ulations of brain n-3 PUFA status suggests that the dopaminergic
system may  be differentially affected depending on the magnitude
and timing of the change in brain DHA status, and could potentially
interact with effects on maternal behaviour or other factors.
Consistent with the complexity of the effects of PUFA manip-
ulations on dopaminergic neurochemistry, the dopamine-related
behavioural changes induced by such treatments also vary between
experiments. Several studies found increased locomotor activity in
adult rats raised on a n-3 PUFA-deﬁcient diet (Bondi et al., 2014;
Levant et al., 2004, 2006c, 2010; Vancassel et al., 2007), although
effects varied depending on the age of the rats and the magnitude
of the decrease in brain DHA (Levant et al., 2006c, 2010). Likewise,
rhesus monkeys with long-term deﬁciency of n-3 PUFAs exhibited
more locomotor activity, as well as stereotyped behaviour, than
those fed a control diet (Reisbick et al., 1994). In another study,
however, adult rats with a 70% decrease in brain DHA exhibited
less exploratory behaviour in a novel environment (Enslen et al.,
1991). Thus, while changes in PUFA status affect the dopaminer-
gic systems involved in motor function, such effects appear to be
highly dependent on the speciﬁc manipulation.
Manipulation of brain DHA content has also been shown to
affect behaviour in animal models of sensorimotor gating (Geyer
and Swerdlow, 1997). In a study with rats, which were raised from
conception on diets varying in n-3 PUFA content, those with low-
est brain DHA levels had signiﬁcant deﬁcits in prepulse inhibition
compared with those with the highest brain concentrations of DHA
(Fedorova et al., 2009). In another study the deﬁcits in prepulse
inhibition observed in Pax6+/− rats, a putative schizophrenia model,
were improved after treatment with AA for 4 weeks after birth
(Maekawa et al., 2009), suggesting a potential role for n-6 PUFAs in
the regulation of sensorimotor gating, at least in this particularly
model.
Glutamatergic neurotransmission which is aberrant in
schizophrenia (Howes et al., 2015) is also affected by PUFAs.
Studies in cultured rat astrocytes and rat brain membrane
preparations indicate that free, but not membrane-bound DHA,
decreased glutamate uptake (Grintal et al., 2009). In in vivo
studies, treatment with n-3 PUFAs attenuated the locomotor
activity, impaired social interactions, inhibition of startle response,
and increased acetylcholinesterase activity induced by the non-atric disorders and preventive medicine. Neurosci. Biobehav. Rev.
competitive NMDA antagonist ketamine (Gama et al., 2012; Zugno
et al., 2014, 2015).
Interestingly, at least some antipsychotic drugs may  affect n-
3 fatty acid homeostasis. Rats treated chronically with risperidone
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nd fed a diet containing ALA had higher erythrocyte and brain DHA
oncentrations than controls (McNamara et al., 2009b), although
ub-chronic haloperidol or clozapine treatment failed to alter brain
HA status in another study of rats fed a standard rat chow (Levant
t al., 2006a).
.1.2. Human studies
As with depression, studies suggest that altered brain PUFA
omposition contributes to the pathogenesis of schizophrenia.
lthough alterations in a variety of long-chain PUFAs have been
bserved, meta-analyses support decreased levels of DHA and AA
n erythrocyte membranes of schizophrenics compared to controls
Hoen et al., 2013; van der Kemp et al., 2012). Moreover, lower
evels of these PUFAs correlated with the severity of symptoms
Bentsen et al., 2012; Montesinos-Rueda et al., 2015; Peet et al.,
996). Similar to the fatty acid differences observed in periph-
ral tissues, several studies have reported alterations in PUFAs and
UFA-related mediators in certain brain regions postmortem. For
xample, although some studies found no differences (Hamazaki
t al., 2015), lower concentrations of several fatty acids including
HA and AA were found in the orbitofrontal cortex of schizophren-
cs relative to controls (Hamazaki et al., 2013; McNamara et al.,
007c). Higher levels of calcium-independent phospholipase A2
nd 5  desaturase, enzymes involved in cleaving PUFAs from
he membrane and PUFA biosynthesis, respectively, were also
ncreased in the brains of schizophrenics (Liu et al., 2009; Rao
t al., 2013; Ross et al., 1999). In addition, several PUFA-related
enes were associated with schizophrenia, or schizophrenia-
elated behaviours, including fatty acid binding protein 7 (Fabp7),
he phospholipase A2G4A BanI polymorphism, and certain single
ucleotide polymorphisms (SNP) of arachidonate 12-lipoxygenase
ALOX12) and Acyl-CoA synthetase medium-chain family member
 (ASCM1) (Kim et al., 2010a,b; Li et al., 2015a,b; Nadalin et al.,
008; Watanabe et al., 2007).
A relatively small number of clinical trials have tested the effects
f PUFA preparations in schizophrenia. Several studies, as well as
 meta-analysis, suggest that n-3 PUFA supplements may  augment
he effects of antipsychotic drugs, but were not sufﬁciently efﬁca-
ious to be used alone (Emsley et al., 2014; Fusar-Poli and Berger,
012; Jamilian et al., 2014; Joy et al., 2006). Another review of clin-
cal trials, however, was unable to draw ﬁrm conclusions regarding
he therapeutic utility of n-3 PUFA supplements in this disease
Politi et al., 2013).
.2. Sphingolipids in schizophrenia
.2.1. Preclinical studies
GalCer are glycosphingolipids predominantly occurring in oligo-
endrocytes. They are involved in myelin function. GalCer was
hown to be enhanced in the frontal cortex of G72Tg mice, which
how a schizophrenia-like phenotype, suggesting that enrichment
f GalCer may  lead to less compact myelin and ultimately to altered
onnectivity in the brain (Wood et al., 2014).
Sphingolipids are abundant lipids not only in the brain, but in
ll tissues. As such it was suggested to use peripheral markers
f sphingolipid activity as a proxy marker for brain pathological
rocesses. A study in ﬁrst-episode treatment-naïve schizophrenics
howed signiﬁcantly reduced total ceramide levels in the skin of
hese patients. However, while levels of some ceramide subspecies
ere decreased, others increased (Smesny et al., 2014). Further-
ore, the validity of peripheral ceramide levels as an indicator ofPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
rain ceramide status remains to be determined. Notably, a study
n rats failed to ﬁnd a quantitative relationship between any single
pecies of ceramide between brain regions and blood (Huston et al.,
016). PRESS
havioral Reviews xxx (2016) xxx–xxx 13
Sphingolipids may  not only play a role in the pathogenesis of
schizophrenia, but also in the therapeutic effects of antipsychotic
drug treatment. Mice that received chronic haloperidol treatment
for 28 days showed, among other metabolomic changes, a signiﬁ-
cant decline in brain sphingosine. Sphingosine is, phosphorylated
to S1P, a potent lipid messenger in the brain. A pathway analysis
in this study also revealed altered sphingolipid metabolism in the
haloperidol-treated animals. The authors suggested that this may
be indicative of altered myelination (McClay et al., 2015). The extent
to which sphingolipid changes during antipsychotic treatment are
markers for the therapeutic action, or are related to side effects, is
currently unclear.
4.2.2. Human studies
The ﬁrst report on sphingolipid metabolism in schizophrenia
showed reduced level of galactocerebrosides, total cerebrosides,
and sulfatides in a single patient (Cherayil, 1969). Sphin-
gomyelin and galactocerebrosides were reduced in postmortem
brain tissue from schizophrenic patients compared to controls
(Schmitt et al., 2004). In other post-mortem studies, brains from
schizophrenics exhibited signiﬁcantly lower amounts of PC and
phosphatidylethanolamine (PE) (Yao et al., 2000), and ceramide
species were more abundant compared to controls, regardless of
treatment with antipsychotic drugs (Schwarz et al., 2008). Alter-
ations in phospholipids in brain tissue were found by in vivo MR
spectroscopy (Fukuzako et al., 1999). A high resolution 31P NMR
spectroscopy study found enhanced sphingomyelin levels in the
occipital, but not frontal or temporal cortex grey matter of post-
mortem schizophrenics. A decrease of ceramide (species: 34:1)
(Schwarz et al., 2008) and an increase of GM3  and GD3 gangliosides
were also observed in untreated schizophrenics (Haselhorst et al.,
1988). Total skin ceramides were reduced in schizophrenia with a
relative increase in subgroups of ceramide species (Smesny et al.,
2014). Altered expression of genes encoding enzymes involved in
sphingolipid metabolism were also found in postmortem brain tis-
sue from schizophrenics, independent of antipsychotic medication
(Narayan et al., 2009). Genotyping and expression analysis showed
an association of N-acylsphingosine amidohydrolase 1 (ASAHI),
delta(4)-desaturase, and sphingolipid 2 (DEGS2) genes with the
susceptibility for schizophrenia (Zhang et al., 2012; Ohi et al., 2015),
and a network analysis of candidate genes supported the involve-
ment of myelin-related pathways (Rietkerk et al., 2009). GalCer was
elevated in the frontal cortex grey and white matter of schizophre-
nia patients in a postmortem shotgun lipidomic analysis, consistent
with ﬁndings from mice with a schizophrenia-like phenotype, sug-
gesting that increased GalCer levels may  contribute to the myelin
dysfunction and disconnectivity observed in the disease.
Not only were sphingolipid species altered in the brain of
schizophrenic patients, but also enzymes that control sphingolipid
metabolism. A postmortem mRNA glycogen expression study
found 18 genes encoding proteins involved in the sphingolipid
pathway differentially expressed in the PFC of schizophrenics with
a duration of illness of less than 5 years. In that study, pro-
found decreases in expression were found for 7 genes including
serine palmitoyltransferase (SPTLC2), sphingosine-1-phosphate
phosphatase (SGPP1), and acid ceramidase 1 (ASAH1). Interest-
ingly, in patients with long term illness ( > 28 years), there was
no reduction in expression of genes involved in sphingolipid
metabolism; however, one sphingolipid metabolism gene, SPTLC2,
was upregulated. These ﬁndings suggest a dysregulation of sphin-
golipid pathways in the brain of schizophrenics during early stages
of illness, which may  be compensated, or reversed by treatment,tric disorders and preventive medicine. Neurosci. Biobehav. Rev.
at later stages (Narayan et al., 2009). Finally, adult patients with
Niemann-Pick disease B and C, often manifest schizophreniform
neuropsychiatric abnormalities, further suggest the involvement of
sphingolipid metabolism in the etiophathogenesis of schizophre-
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ia (Josephs et al., 2003; Richa et al., 2009; Walterfang et al., 2006).
aken together, abnormalities in the level, metabolism, and genetic
egulation of sphingolipids have been found in brain tissue as well
s in the periphery, consistent with the membrane hypothesis of
chizophrenia (Horrobin et al., 1994). However, the precise roles of
ingle sphingolipids in schizophrenia remain to be determined.
.3. Endocannabinoids in schizophrenia
.3.1. Preclinical ﬁndings
Evidence from human and animal research indicates that
annabis use, in particular during critical developmental periods
uch as puberty and adolescence, acts as a modest statistical risk
actor for the emergence of psychosis, ranging from psychotic
ymptoms such as hallucinations and delusions to clinically signif-
cant disorders such as schizophrenia (Caspi et al., 2005; Konings
t al., 2008; Arseneault et al., 2004; Schneider, 2008; Rubino et al.,
015; Leweke and Schneider, 2011; Radhakrishnan et al., 2014).
ost studies on the role of cannabinoids in schizophrenia have
ocused on the impact of exogenous cannabinoids on psychosis.
owever, independent of previous cannabis use, a dysfunctional
CB system has also been implicated in the etiopathogenesis of
chizophrenia (Rubino et al., 2015; Marco et al., 2011; Emrich
t al., 1997). The eCB system plays an active role in brain regions
isturbed in schizophrenia and interacts with the main neu-
otransmitters thought to be involved in the pathophysiology
f schizophrenia. Analysis of eCB levels in animal models of
chizophrenia revealed controversial results depending on, among
ther things, the model and experimental design used and the tim-
ng of analysis, i.e. before or after the behavioural testing. One study
mploying chronic phencyclidine (PCP) administration reported a
on-signiﬁcant reduction in AEA levels in the PFC, whereas 2-AG
ontent was increased in that region (Vigano et al., 2009). In con-
rast, in a similar pharmacological model, increases in AEA levels
n the Nacc and VTA were observed, whereas 2-AG levels were
ncreased only in the VTA (Seillier et al., 2010). More recently, the
ame group found reduced AEA levels in the PFC and amygdala
hen PCP-treated rats underwent a social interaction test (Seillier
t al., 2013). Isolation rearing in rats, another classical model of
spects of schizophrenia, induced up- as well as down-regulation
f 2-AG contents in a brain region speciﬁc manner, while AEA levels
emained unaffected (Zamberletti et al., 2012).
Inhibition of FAAH, and subsequent AEA elevation, improved
ehavioural performance in animal models of schizophrenia
Seillier et al., 2013), supporting the hypothesis for a protective role
f AEA in psychosis (Giuffrida et al., 2004). In line with these ﬁnd-
ngs, the non-psychoactive compound, cannabidiol (CBD), which
as been shown to exert some of its pharmacological actions via
nhibition of FAAH, has been suggested to possess antipsychotic
roperties in schizophrenic patients and preclinical models for
chizophrenia (Leweke et al., 2012; Hermann and Schneider, 2012).
.3.2. Human studies
There is accumulating evidence from clinical research suggest-
ng that AEA dysfunction plays a crucial role in schizophrenia.
lterations in eCB levels in schizophrenic patients were reported
n peripheral blood samples (De Marchi et al., 2003), CSF (Leweke
t al., 1999; Giuffrida et al., 2004; Leweke et al., 2007), and post-
ortem brain tissue (Muguruza et al., 2013). The ﬁrst evidence
or eCB alterations in schizophrenia was reported by Leweke et al.
1999), who observed elevated levels of AEA and PEA in the CSF
f schizophrenic patients compared to healthy controls. 2-AG wasPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
ot analysed, as it was not present at a detectable level. This ini-
ial ﬁnding was replicated in a larger sample of schizophrenic
nd other psychiatric patients (Giuffrida et al., 2004). Notably, a
igniﬁcant elevation of AEA in CSF of antipsychotic-naïve, ﬁrst PRESS
havioral Reviews xxx (2016) xxx–xxx
episode schizophrenic patients was found, while serum eCB levels
remained unaffected. In addition, CSF AEA levels were signiﬁcantly
decreased and inversely correlated to psychotic symptoms (in par-
ticular with negative symptoms) in schizophrenics, with no such
alterations detected in patients with dementia or affective disor-
ders. In contrast to these ﬁndings, another study reported higher
AEA levels in whole blood of schizophrenic patients compared
to controls, and clinical remission was accompanied by a signiﬁ-
cant drop in AEA contents and the mRNA transcript for FAAH (De
Marchi et al., 2003). Consequently, eCB measurements in periph-
eral blood samples have been criticized, and it is debated whether
alterations in peripheral blood reﬂect changes in the brain and vice
versa. Nevertheless, Koethe et al. (2009) reported elevated CSF AEA
levels in early psychosis. Interestingly, patients with lower AEA
levels showed a higher risk for a transition to psychosis earlier,
while higher AEA levels correlated with a delayed transition to
psychosis. This anandamidergic up-regulation in the initial prodro-
mal  course was, therefore, suggested to indicate a protective role
of the eCB system in early schizophrenia. Hence, pharmacologi-
cal treatment that increases AEA content may  possess therapeutic
value in schizophrenia, as has been suggested by preclinical stud-
ies. Consistent with this hypothesis, CBD produced a decrease
in the psychotic symptoms of schizophrenia, which was accom-
panied by a signiﬁcant increase in serum AEA levels, and also
displayed a markedly superior side-effect proﬁle to the antipsy-
chotic drug amisulpride. Thus, the inhibition of AEA deactivation
may  contribute to the antipsychotic effects of CBD (Leweke et al.,
2012). Although the data implicate a strong involvement of AEA in
schizophrenia, the detailed role of eCB signalling in this disorder
remains yet to be clariﬁed. A recent study measured eCB levels in
postmortem brain tissue from schizophrenic patients and reported
elevated levels of 2-AG in the hippocampus, cerebellum, and PFC.
AEA levels were decreased in these regions. These postmortem data
appear to challenge the assumption that alterations of AEA levels
in CSF reﬂect levels of eCBs in the brain. The discrepancies noted
between eCB levels in the brain and whole blood may  be the con-
sequence of the modiﬁed immune response observed in the course
of schizophrenia (De Marchi et al., 2003). Furthermore, substan-
tial changes in eCB content occur postmortem, highlighting the
importance of the postmortem interval in studies of brain AEA and
2-AG content (Palkovits et al., 2008; Buczynski and Parsons, 2010).
Therefore, more studies will be needed to identify the physiologi-
cal range of eCB concentrations present in various brain regions of
schizophrenic patients.
4.4. Preventive medicine in schizophrenia
Preclinical and clinical research demonstrates that phospho-
lipids, sphingolipids, and eCBs are involved in the ethiopathology
of schizophrenia. Supplementation with n-3 fatty acids alters intra-
cellular phospholipase A2 activity and membrane fatty acid proﬁles
and reduces the risk of progression to ﬁrst-episode psychotic dis-
order in young adults with subthreshold psychosis (Amminger
et al., 2010, 2015; Smesny et al., 2014). Studies for the prevention
of recurrence of schizophrenic psychoses are currently underway
(Pawelczyk et al., 2015). Chronic malnutrition, during which the
diet lacks sufﬁcient n-3 PUFAs, as well as other nutrients, appears
to enhance the risk of schizophrenia and worsen the symptoms
after onset. This is mediated by a reduced DHA content in the
brain which affects prominent neurotransmitter systems crucially
involved in schizophrenia and antipsychotic action. Much likeatric disorders and preventive medicine. Neurosci. Biobehav. Rev.
for depression/anxiety, prevention, or at least limitation, of the
schizophrenia risk can be achieved by means of nutrition. Notably,
current evidence suggests that a diet high in n-3 PUFAs may  have
protective effects against schizophrenia, and may also have some
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inor effects on symptoms once the disease manifests. Thus, n-3
UFA supplementation may  be used to improve therapy outcome.
Accumulating evidence also indicates that sphingolipid
omoeostasis is disrupted in schizophrenia. Various ceramide
pecies appear to accumulate in the brain, which causes a dys-
unction in membrane regulation and signalling. To prevent the
eramide accumulation, a life style with low stress, no alcohol
buse, and physical activity, all of which reduce ceramide levels,
ay  serve as preventive measure to limit this risk factor for
chizophrenia.
Endocannabinoids have long been considered to be a factor that
ay, when dysregulated, facilitate development of schizophrenia
Berger et al., 2006). Most notably, chronic or acute hyperstimu-
ation of CBRs in the brain, resulting from cannabis use, may  lead
o schizophrenia-like symptoms. An obvious preventive measure
ould, therefore, be to abstain completely from any type of drug-
nduced CBR stimulation, thus avoiding cannabis and other drugs
ike herbal/legal high preparations (Müller et al., 2015). The poten-
ial efﬁcacy of psychopharmacological interventions that reduce
CB activity as a preventive treatment for schizophrenia is currently
nclear and awaits further research.
. Lipids in drug addiction
.1. Fatty acids and phospholipids in drug addiction
.1.1. Preclinical ﬁndings
Little work has been done speciﬁcally investigating the role
f brain phospholipids in addiction. The studies discussed above
ndicating alterations in function of the mesolimbic dopamine sys-
em, which mediates the reinforcement and reward functions that
re fundamentally involved in addiction, in animals raised on n-3
UFA-deﬁcient diets suggest the potential for brain phospholipids
o impact addiction. Studies have also shown that sensitization, a
rocess hypothesized to contribute to the development of addiction
Di Chiara, 1995; Robinson, 1993), to amphetamine is augmented
n mice with diet-induced n-3 fatty acid deﬁciency (McNamara
t al., 2008a,b). Likewise, the n-3 PUFA EPA is required for normal
esponse behaviours and tolerance to alcohol in C. elegans, further
uggesting a potential role for PUFA in addiction (Raabe et al., 2014).
.1.2. Human studies
The role of phospholipids and PUFA in humans with addiction
as yet to be explored.
.2. Sphingolipids in drug addiction
.2.1. Preclinical ﬁndings
The investigation of preclinical models has provided strong
vidence that the acute effects of drug use involve changes in
phingolipid metabolism. A widely accepted view is that the over-
roduction of the pro-apoptotic lipid second messenger ceramide
ould play a central role in the emergence of drug-related disorders.
or instance, ceramide upregulation was suggested to be a crucial
athogenic element in a mouse model of emphysema, a prevalent
uman disease primarily caused by cigarette smoking (Petrache
t al., 2005). Likewise, alcohol-induced conditions such as alcoholic
iver disease or alcohol-induced neurotoxicity have been associated
ith the generation of ceramide (Yang et al., 2015, 2016. Chronic
onsumption of alcohol was further shown to alter brain ceramide
nd sphingomyelin concentrations in rodents in a region-speciﬁcPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
anner (Roux et al., 2015). Altered brain ceramide metabolism
as also observed in a mouse model of binge drinking (Bae et al.,
014), where ceramide levels decreased during acute intoxication,
ut increased during withdrawal from alcohol. This biphasic effect PRESS
havioral Reviews xxx (2016) xxx–xxx 15
might indicate that the consequences of alcohol-induced sphin-
golipid alterations are not exclusively neurotoxic, but may be also
protective and adaptive (Bae et al., 2014).
Few studies have examined the effects of drugs of abuse, other
than alcohol and nicotine on sphingolipids. In a murine model of
tolerance to opioid-induced antinociception, the repeated adminis-
tration of morphine resulted in increased activity of SPT, CerS, and
ASM in the spinal cord (Ndengele et al., 2009). In another study,
repeated intraperitoneal injection of rats with amphetamine and
ethanol resulted in a substance-speciﬁc alteration of the concen-
tration of different gangliosides (Haselhorst et al., 1991). Repeated
administration of a moderate dose of cocaine in rats led to an accu-
mulation of more complex gangliosides (GM1, GD1a, GD1b, GT1b
and GQ1b) and a reduction of precursors (GM3, GM2, GD3 and GD2)
in the liver (Cabello et al., 1994). This high sensitivity of sphingolipid
metabolism to a broad spectrum of stimuli, suggests that the acute
effects of drugs of abuse in general involve sphingolipid-related
alterations.
The answer to the question of whether aberrant sphingolipid
metabolism can inﬂuence drug-related behaviour is less clear. Since
sphingolipids are involved in the regulation of ion currents and
the secretion, uptake, and signalling of neurotransmitters and hor-
mones including effects on well-known molecular targets in drug
addiction (e.g. AMP  kinase, BDNF, CREB), there is broad theoretical
overlap of sphingolipid metabolism and addiction biology. More-
over, sphingolipids have been shown to be functionally linked
to fundamental processes such as neuroplasticity and learning
which are relevant for the transition from occasional drug use to
addiction (Wheeler et al., 2009). Interestingly, in alcohol-preferring
rats a potentially favourable ceramide proﬁle was observed fol-
lowing chronic voluntary ethanol consumption (Godfrey et al.,
2015). This might indicate that drug-related behaviour can be
utilized to regulate, and possibly even normalize, dysregulated
sphingolipid metabolism. Unfortunately, the authors did not men-
tioned whether alcohol-preferring rats per se exhibited altered
sphingolipid levels in comparison to their alcohol-non-preferring
counterparts (Godfrey et al., 2015).
Initial studies of the impact of sphingolipids on addiction-
related behaviour focused on gangliosides. Gangliosides play a
role in synaptic plasticity and may, thus, contribute to the adap-
tive changes following drug experience. Long-term administration
of GM1  in mice decreased the acute excitatory and behavioural
sensitization effects of ethanol (Bellot et al., 1996), as well
as amphetamine-induced hyperlocomotion (Bellot et al., 1997).
Another group reported that the development of morphine toler-
ance and dependence was greatly reduced by the co-administration
of GM1  by a mechanism involving the translocation of protein
kinase C to the plasma membrane (Mayer et al., 1995). In another
model, pre-treatment with GM1  enhanced the rewarding prop-
erties of cocaine in the conditioned place preference paradigm
(Valdomero et al., 2010), which was subsequently shown to involve
increased BDNF protein levels in the Nacc (Valdomero et al., 2015).
Yet another work suggested that ceramide might be involved in
drug adaptation. In a murine model of tolerance to opioid-induced
antinociception, the repeated administration of morphine resulted
in increased ceramide level. The inhibition of ceramide biosynthe-
sis with various pharmacological inhibitors signiﬁcantly attenuated
the increase in spinal ceramide production and the development
of tolerance to morphine’s antinociceptive effects (Ndengele et al.,
2009).
Consistent with a role for sphingolipids in addiction-related
behaviour, modulation of dopamine release or uptake by sph-tric disorders and preventive medicine. Neurosci. Biobehav. Rev.
ingolipids has also been reported. For example, in the rat
pheochromocytoma PC12 cell line, treatment with the Ca2+-
ionophore A23187 resulted in dopamine release and production
of ceramide via the sphingomyelin pathway, both of which were
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revented by the inhibition of the A23817-mediated Ca2+ inﬂux by
ddition of chelator EGTA (Jeon et al., 2005). Furthermore, treat-
ent of PC12 cells with cell-permeable ceramide increased the
ate of dopamine release in the presence of A23187 (Jeon et al.,
005). In another study in PC12 cells, siRNA-mediated or pharma-
ological inhibition of NSM-2 resulted in decreased ceramide level
nd decreased dopamine uptake, whereas treatment with cell-
ermeable ceramide induced a concentration-dependent increase
n dopamine uptake (Kim et al., 2010a,b). Hsp60 was  subsequently
hown to be a regulator of NSM-2-mediated ceramide produc-
ion and the concomitant dopamine uptake (Ahn et al., 2013). In
ivo, the inhibition of the ceramide de novo pathway via myriocin
reatment resulted in increased dopamine levels in the striatum
nd hippocampus and reduced dopamine in the cortex, as well
s changes in other neurotransmitter systems (Osuchowski et al.,
004). Other studies employing the ceramide synthase inhibitor
umonisin B1 did not ﬁnd differences in brain dopamine concen-
rations in BALB/c mice (Tsunoda et al., 1998) or in rats (Porter
t al., 1993), but did ﬁnd effects on the norepinephrine:dopamine
atios in rats, or increased homovanillic acid levels and decreased
-HT levels in mice. Besides these effects on exo- and endocytic
rocesses, little is known about molecular mechanism involving
phingolipids in addiction-related behaviours.
Sphingosine (Sph), a breakdown product of ceramide, is an
ndogenous competitive regulator of the sigma 1 receptor (S1R;
amachandran et al., 2009). The interaction with S1R was speciﬁc
or Sph, and not observed for ceramide or sphingosine-1-phosphate
Ramachandran et al., 2009). The S1R is found in the CNS and in
ost peripheral tissues, and is primarily localized in the endoplas-
ic  reticulum. It functions as a molecular chaperone and has been
hown to play a regulatory role in many cell signalling systems,
ncluding several types of GPCRs and voltage-gated ion channels.
arious pharmacological agents including drugs of abuse such as
ocaine and methamphetamine bind to S1R, which mediates some
f their neuropharmacological effects (Tsai et al., 2014). In fact, acti-
ation of S1R was required for establishing the rewarding effect
f cocaine in a conditioned place preference paradigm (Romieu
t al., 2002). Furthermore, S1R agonists facilitated the reinforcing
ffects of ethanol and the induction of binge-like drinking (Sabino
t al., 2011), whereas S1R antagonists blocked excessive drinking in
lcohol-preferring rats (Sabino et al., 2009). Thus, the regulation of
1R might be a promising link between sphingolipid metabolism
nd drug addiction. Of note, a single administration of alcohol to
regnant mice induced a more than two-fold increase in the con-
entration of sphingosine in the brains of progeny (Dasgupta et al.,
007).
.2.2. Human studies
In human studies, ASM activity was increased in blood cells of
ntoxicated alcohol-dependent patients (Reichel et al., 2010). Fur-
her evidence for alcohol-induced activation of the ASM/ceramide
ystem came from the analysis of secretory ASM in blood plasma
Kornhuber et al., 2015), where alcohol-dependent patients exhib-
ted increased ASM activity in comparison to healthy controls
Reichel et al., 2011; Mühle et al., 2014). Alcohol addiction, there-
ore, is associated with altered circulating blood lipids that might
epresent potential biomarkers for the disease (Reichel et al., 2015;
eikle et al., 2015). Likewise, increased lung ceramides in individ-
als with smoking-induced emphysema suggests a crucial role forPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
eramide upregulation in human drug-related diseases (Petrache
t al., 2005). However, whether sphingolipids are involved in the
rug-related behaviour of humans or the neuro-adaptation leading
o addiction is currently not known. PRESS
havioral Reviews xxx (2016) xxx–xxx
5.3. Endocannabinoids in drug addiction
5.3.1. Preclinical ﬁndings
Along with the dopaminergic, the glutamatergic, and the
endogenous opioid system, the eCB system has emerged recently
as a key neurochemical mediator of reward processes with impli-
cations for addictive disorders (Parsons and Hurd, 2015; Friemel
et al., 2014; Fattore et al., 2010; Moreira et al., 2015). It has been
well known for centuries that cannabinoids can induce euphoric
and rewarding effects in humans and animals. The most prominent
feature of consumption of cannabis products is an initial period
of euphoria and relaxation. These pleasurable subjective effects
most likely contribute to its abuse (Ameri, 1999). Growing evidence
implicates the eCB system as a strong modulator of various aspects
of drug and non-drug reward (Cota et al., 2006; Fattore et al., 2010;
Kirkham, 2009; Panagis et al., 2014; Leishman et al., 2013). Com-
ponents of the eCB system are widely distributed throughout the
brain reward circuits, and eCB signalling exerts a direct or indi-
rect modulatory inﬂuence on all other neurotransmitter systems
involved in the mediation of reward-related behaviours (Parsons
and Hurd, 2015). Furthermore, eCBs are also necessary for the
induction of several dopamine-dependent or -independent long-
term forms of synaptic plasticity, such as long-term depression and
long-term potentiation, in the VTA and in the terminal regions of
dopaminergic projections (Kauer and Malenka, 2007). Thus, the eCB
system is part of the neurobiological sequelae underlying system-
atic drug use and the development of addictive behaviours (Müller
and Schumann, 2011a,b; Luchicchi and Pistis, 2012; Müller and
Homberg, 2015). Given the abuse potential of cannabinoid agonists
and the strong impact of the eCB system on basic reward process-
ing, a plethora of preclinical studies has addressed the role of eCB
signalling in various aspects of addictive behaviours for all classes
of drugs of abuse, as well as natural rewards. A complete overview
of the role of eCBs in addiction is beyond the scope of the present
review. Accordingly, here we will focus on the rewarding proper-
ties of eCBs and their interaction with alcohol, nicotine, opioids and
psychostimulants.
AEA and 2-AG are self-administered by nonhuman primates
(Luchicchi and Pistis, 2012) and rodents (De Luca et al., 2014) indi-
cating their reinforcing properties. However, the mechanisms by
which elevated levels of eCBs produce rewarding effects through
FAAH/MAGL inhibition are less clear. Neither FAAH nor MAGL
inhibitors induced reinforcing effects or 9-tetrahydrocannabinol
(THC)-like psychotropic effects in laboratory rodents. Therefore,
they appear to possess little abuse potential. Furthermore, the
FAAH inhibitors, URB597 and PMSF, did not alter brain stimula-
tion reward thresholds. Nevertheless, dual FAAH/MAGL inhibition,
and to some extent also high doses of the MAGL inhibitor JZL184,
exerted cannabimimetic effects. Likewise, chronic FAAH inhibition
did not induce any withdrawal symptoms after CB1R blockade
in a rimonabant-precipitated withdrawal procedure, while such
symptoms were observed after chronic treatment with the MAGL
inhibitor JZL184 (Fowler, 2015; Blankman and Cravatt, 2013;
Luchicchi and Pistis, 2012). Chronic treatment with the exogenous
cannabinoid THC decreased AEA and 2-AG levels in the rat striatum,
and levels of AEA but not 2-AG in the midbrain and diencephalon.
The CB1R antagonist/inverse agonist rimonabant increased AEA
release in the rat hypothalamus, whereas opposite changes were
observed for 2-AG release (Panlilio et al., 2013).
Substantial evidence indicates that non-cannabinoid drugs of
abuse, such as alcohol, nicotine, opioids, and cocaine, can alter AEA
and 2-AG levels in reward-related areas of the rodent brain. How-atric disorders and preventive medicine. Neurosci. Biobehav. Rev.
ever, several factors such as the brain region evaluated, time point
of measurement after drug exposure, and the nature of drug expo-
sure (voluntary intake vs. non-voluntary administration) appear
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o have an important impact on the direction of these alterations
Serrano and Parsons, 2011; Parsons and Hurd, 2015). Repeated
icotine injections increased AEA content in the limbic forebrain,
nd AEA and 2-AG contents in the brainstem. Hippocampal and
ortical levels of both eCB were decreased, whereas, in the stria-
um, there was a decrease in AEA only (Gonzalez et al., 2002).
ntravenous nicotine self-administration increased extracellular
evels of both AEA and 2-AG in the rat VTA measured by micro-
ialysis. Interestingly, although VTA 2-AG levels were elevated by
oth voluntary and forced (yoked administration) nicotine expo-
ure, VTA AEA levels were increased only by voluntary nicotine
elf-administration (Buczynski et al., 2013). Surprisingly, given
hese ﬁndings on elevated AEA levels by nicotine and that CB1R
ntagonism with rimonabant has been suggested as potential ther-
peutic agent for smoking cessation, there is evidence from a series
f experiments in rats and monkeys that FAAH inhibition might
ounteract the addictive effects of nicotine (Panlilio et al., 2013;
uchicchi and Pistis, 2012). In agreement with these behavioural
ndings, microdialysis and electrophysiology studies indicate that
AAH inhibition reduces nicotine-induced dopamine elevations
n the Nacc shell and blocks nicotine-induced increases in ﬁring
ate and burst ﬁring of VTA dopaminergic neurons (Luchicchi and
istis, 2012). Although the involvement of AEA and CB1R in these
ffects is not yet completely understood, it is hypothesized that
he effects are largely due to activation of peroxisome proliferator-
ctivated receptors (PPAR). The inhibition of FAAH not only raises
EA levels, but also concentrations of other non-cannabinoid N-
cylethanolamides, i.e., OEA and PEA, which act as endogenous
PAR ligands (Melis et al., 2008; Luchicchi and Pistis, 2012).
Similar to nicotine, chronic ethanol exposure seems to induce
egion-speciﬁc changes in eCB levels in the rodent brain. Ethanol-
nduced alterations in eCBs appear to be observed most consistently
n striatal regions, but not in frontal cortical areas, although
nconsistencies between studies hinder conclusions regarding the
irection of change and the brain regions involved (Parsons and
urd, 2015; Pava and Woodward, 2012). Acute or short-term
thanol exposure decreased eCB signalling, while chronic alcohol
xposure appears to be associated with increased formation of AEA
nd 2-AG contents (Hungund et al., 2002; Pava and Woodward,
012; Panlilio et al., 2013). As reported previously for nicotine, the
ature of drug exposure may  play an important role. Forced chronic
thanol intake was reported to result in a decrease in levels of
oth AEA and 2-AG in the midbrain, while it increased AEA content
n the limbic forebrain (Gonzalez et al., 2002). In contrast, self-
dministration of alcohol increased 2-AG levels, but did not alter
EA levels in the Nacc shell (Caille et al., 2007). This effect was  more
ronounced following voluntary self-administration compared
ith non-contingent alcohol exposure. Hence, brain eCB signalling
ppears to be inﬂuenced not only by drug-related pharmacologi-
al effects but, also by motivational aspects of reward processing,
uch as neural activity engaged by active drug self-administration
Parsons and Hurd, 2015). Pharmacological inhibition or genetic
eletion of FAAH increased operant self-administration and pref-
rence for ethanol in rats and mice (Parsons and Hurd, 2015; Pava
nd Woodward, 2012). In addition, an association of impaired FAAH
ctivity with alcohol reward is supported by the ﬁndings that an
lcohol-preferring phenotype in rats can be established by injecting
he FAAH inhibitor, URB597, into the PFC (Hansson et al., 2007).
Functional and cellular cross-talk between the eCB and the
ndogenous opioid systems is well established. CB1R and -opioid
eceptors share a similar distribution throughout the reward cir-
uits and are co-localized, in particular in the Nacc and the dorsalPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychia
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
triatum (Parolaro et al., 2010; Lopez-Moreno et al., 2010). In addi-
ion, heterodimerization of CB1R receptors with opioid receptors
as been reported. Simultaneous activation of CB1R and -opioid
eceptors attenuates stimulation of G-proteins or MAPK compared PRESS
havioral Reviews xxx (2016) xxx–xxx 17
to activation of either receptor alone (Smith et al., 2010; Lopez-
Moreno et al., 2010). In the preponderance of preclinical studies,
exposure to opioids increased AEA and decreased 2-AG tissue con-
centrations in the striatum, limbic forebrain and hippocampus
(Parsons and Hurd, 2015; Panlilio et al., 2013). FAAH inhibition did
not alter the reinforcing efﬁcacy of heroin in an operant procedure;
however, increasing AEA levels by AM404, a putative AEA trans-
port inhibitor, decreased the reinforcing efﬁcacy of heroin. These
ﬁndings led to the conclusion that modulation of the reinforcing
effects of heroin by CB1R activation or inhibition is not due to an
opioid-induced release of eCBs, but rather to interactions between
opioid receptors and CB1R and their signalling pathways (Solinas
and Goldberg, 2005; Panlilio et al., 2013).
Although eCB signalling appears to exert some modulatory
impact on the rewarding properties of psychostimulants, this inﬂu-
ence appears to be modest, and the detailed role of the eCB
system in cocaine reward and addiction remains to be clariﬁed
(Oliere et al., 2013; Panlilio et al., 2013). Psychostimulants, such
as cocaine, generally produce modest disruptions in brain eCB lev-
els in rodents, with subtle increases in 2-AG in forebrain regions
after acute administration and decreases in 2-AG concentration
following chronic cocaine exposure. No such changes have been
described for AEA. FAAH inhibition does not appear to alter the
direct reinforcing effects of cocaine, but might provide protection
against cue-induced relapse. Moreover, voluntary cocaine self-
administration in the rat did not alter extracellular Nacc eCB levels,
but did decrease levels of hippocampal and cortical 2-AG (Panlilio
et al., 2013; Parsons and Hurd, 2015).
5.3.2. Human studies
Human studies aimed at understanding of the role of eCB
signalling in addiction are rare and have primarily focused on
alcoholism. Postmortem studies show enhanced AEA and 2-AG
levels in the dorsolateral PFC of alcoholic suicide victims, but not
alcohol-dependent non-suicides (Vinod et al., 2005). Activity and
expression levels of FAAH were decreased in alcoholics compared
to controls, but this decrease was  lower in alcoholic suicides com-
pared to non-suicides (Vinod et al., 2010). In contrast, a recent study
reported decreased MAGL activity in the PFC of alcoholics (suicide
and non-suicide victims), while protein levels of FAAH and MAGL
were unaltered (Erdozain et al., 2015). However, it remains quite
difﬁcult to draw conclusions on physiological eCB levels in the brain
from postmortem analyses, in particular when taking into consider-
ation that the cause of death (suicide vs non-suicide) per se appears
to impact on eCB levels.
In healthy social drinkers, visual alcohol cues were found to
increase plasma AEA levels, whereas neutral and stress-related
images had no such effect. Notably, baseline and response AEA lev-
els in these subjects were negatively and positively correlated with
self-reported alcohol craving scores, respectively. Cue-induced
increases in heart rate were also correlated with AEA. How-
ever, recently detoxiﬁed alcoholics had signiﬁcantly lower baseline
plasma AEA levels than non-dependent social drinkers. Although
alcohol-related cues elicit more-intense cravings in alcoholics,
these individuals did not present signiﬁcant cue-induced increases
in plasma AEA (Mangieri et al., 2009). This blunted AEA response
may  reﬂect aberrant eCB processing in alcoholics. Nonetheless, fur-
ther studies are required to conﬁrm a direct link between this
potential peripheral biomarker and brain eCB levels (Parsons and
Hurd, 2015).
An increased vulnerability to drug and alcohol abuse in humans
has been linked to a polymorphism in the FAAH gene. The SNPtric disorders and preventive medicine. Neurosci. Biobehav. Rev.
rs324420 results in a missense mutation of a C–A replacement
at position 385. This leads to a proline to threonine exchange at
protein position 129. This C385A SNP is functional and results in
reduced FAAH expression and activity, and hence increases plasma
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oncentrations of AEA and other N-acylethanolamine FAAH sub-
trates in individuals with the A/A genotype. This genetic disruption
as been strongly implicated in addiction-related behaviours,
ncluding enhanced impulsivity and increased anxiety sensitivity,
s well as increased risk for drug use (Sipe et al., 2002; Chiang et al.,
004; Buhler et al., 2014; Parsons and Hurd, 2015).
FAAH-based treatments have not yet been approved for human
se, but preclinical ﬁndings indicate that they might show promise
or treating a wide range of disorders, including drug addic-
ion. Early clinical trials with FAAH inhibitors suggest that these
rugs are well tolerated, but clariﬁcation of their abuse potential
equires further evaluation (Panlilio et al., 2013; Fowler, 2015).
 clinical trial investigating the safety and efﬁcacy of the FAAH
nhibitor PF04457845 for the treatment of cannabis dependence in
umans is currently being performed at the Yale School of Medicine
NCT01618656), with results expected in December 2016.
.4. Preventive medicine for drug addiction
Drug addiction is a disorder that develops out of controlled drug
se and instrumentalization of drug effects, which is often endorsed
y society (Müller and Schumann, 2011a,b; Müller, 2013). A second
ajor factor in the etiopathology of drug addiction is the transi-
ion from controlled drug use to compulsive use. Currently there
s still little evidence for a crucial role of phospholipids and PUFAs
n brain neuronal adaptations that lead to compulsive drug taking.
owever, monoaminergic systems, which undergo major changes
uring this transition (Müller and Homberg, 2015), are affected by
hysicochemical properties of the cell membrane, which is at least
artially dependent on its phospholipid composition. Thus, a con-
ributory role for PUFAs in addiction development is very likely.
ccordingly, investigations to mitigate the transition to compulsive
rug use by changing PUFA content in the diet are warranted.
Sphingolipids have been implicated in many organ pathologies
aused by chronic consumption of several addictive drugs, many
f which result in upregulation of ceramide species in peripheral
issue. However, neurotoxic effects of ceramides have also been
bserved in the brain. In contrast, little is known about how sph-
ngolipids contribute to the systematic establishment of drug use
ehaviours and the loss of control over those behaviours. A recent
tudy suggested that a temporal decline in ceramides may facilitate
e-learning (Huston et al., 2016). This suggests that interventions
hat reduce ceramide load, like the Mediterranean diet or stress
eduction, could facilitate the establishment of behaviours that
ompete with drug-related activities.
A role of the eCB system in drug use and addiction is well estab-
ished. Most notably, direct stimulation of the CBRs with exogenous
igands, like THC, can lead to an addiction for those substances.
owever, a growing body of evidence indicates the eCB mediates
ffects contributing to addiction to other drugs, in addition to THC.
lthough the eCB can be manipulated by a wide range of pharma-
ological tools experimentally, no approved effective treatment or
reventive measure has emerged yet.
. Conclusion and outlook
Accumulating evidence from preclinical and clinical studies sug-
ests an important role for the lipid systems in major psychiatric
isorders. Phospholipids and sphingolipids predominantly shape
hysical properties of cell membranes, while endocannabinoids
re involved in cell signalling. Lipids thus represent important lociPlease cite this article in press as: Schneider, M.,  et al., Lipids in psychi
(2016), http://dx.doi.org/10.1016/j.neubiorev.2016.06.002
or synaptic plasticity. Increasing evidence shows that neuronal
embranes are not static as previously believed, but are highly
ynamic in their lipid composition and, thus, in their microphys-
cal properties. This dynamic regulation of the physical properties PRESS
havioral Reviews xxx (2016) xxx–xxx
of the membrane inﬂuences how neurotransmitters interact with
membrane-bound signalling proteins, consequently modulating
transmembrane information transfer. Findings summarized here
highlight emerging models of how lipid systems act as highly plastic
components of neuronal systems that inﬂuence their function.
Given this important role for lipids in cell function and plas-
ticity, it is clear that dysfunction in any of the lipid systems may
contribute to the etiopathology of psychiatric disorders including
mood disorders, schizophrenia, and drug addiction. Furthermore,
lipid systems may  be altered as a consequence of a primary disor-
der, such as drug addiction, which can then lead to co-morbidities
in peripheral organs.
The data presented here suggest that the use of nutritional
and other treatments aimed at modulating the function and reg-
ulation of the PUFA/phospholipid, sphingolipid, and eCB systems
represent a means to not only improve function and outcomes in
individuals suffering from mood disorders, schizophrenia, and drug
addiction, but may  also serve as means of prevention. Accordingly,
these approaches, particularly nutritional treatments, represent
readily implementable, inexpensive interventions with emerging
mechanistic bases. Furthermore, the reviewed ﬁndings support
additional investigation of the use of these in interventions as pre-
ventative and ameliorative treatments for psychiatric disorders.
Future investigation must include controlled randomized trials to
determine clinical efﬁcacy, as well as the appropriate formulations,
optimal doses, and durations of treatment. Additional studies must
fully elucidate the mechanisms by which lipid mediators mitigate
the pathophysiology of these psychiatric disorders, and whether
the effects differ depending whether the treatment is used for pre-
vention or treatment. The effects of patient characteristics, such as
age and gender, on response to lipid interventions also remain to
be determined.
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